IgM and IgD B cell receptors differentially respond to endogenous antigens and control B cell fate.

Permalink
https://escholarship.org/uc/item/26h0q5v1

Authors
Noviski, Mark
Mueller, James L
Satterthwaite, Anne
et al.

Publication Date
2018-03-09

DOI
10.7554/elife.35074

Peer reviewed
IgM and IgD B cell receptors differentially respond to endogenous antigens and control B cell fate

Mark Noviski¹, James L Mueller², Anne Satterthwaite³, Lee Ann Garrett-Sinha⁴, Frank Brombacher⁵, Julie Zikherman²*

¹Biomedical Sciences (BMS) Graduate Program, University of California San Francisco, San Francisco, United States; ²Rosalind Russell and Ephraim P. Engleman Arthritis Research Center, Division of Rheumatology, Department of Medicine, University of California San Francisco, San Francisco, United States; ³Department of Immunology, UT Southwestern Medical Center, Dallas, United States; ⁴Department of Biochemistry, University at Buffalo, The State University of New York, Buffalo, United States; ⁵International Center for Genetic Engineering and Biotechnology (ICGEB), Cape Town, South Africa; ⁶Institute of Infectious Diseases and Molecular Medicine, Division of Immunology, Faculty of Health Sciences, University of Cape Town & Medical Research Council (SAMRC), Cape Town, South Africa

Abstract Naive B cells co-express two BCR isotypes, IgM and IgD, with identical antigen-binding domains but distinct constant regions. IgM but not IgD is downregulated on autoreactive B cells. Because these isotypes are presumed to be redundant, it is unknown how this could impose tolerance. We introduced the Nur77-eGFP reporter of BCR signaling into mice that express each BCR isotype alone. Despite signaling strongly in vitro, IgD is less sensitive than IgM to endogenous antigen in vivo and developmental fate decisions are skewed accordingly. IgD-only Lyn⁻/⁻ B cells cannot generate autoantibodies and short-lived plasma cells (SLPCs) in vivo, a fate thought to be driven by intense BCR signaling induced by endogenous antigens. Similarly, IgD-only B cells generate normal germinal center, but impaired IgG1⁺ SLPC responses to T-dependent immunization. We propose a role for IgD in maintaining the quiescence of autoreactive B cells and restricting their differentiation into autoantibody secreting cells.

DOI: https://doi.org/10.7554/eLife.35074.001

Introduction

The pre-immune mature naïve B cell compartment must balance the need for a diverse antibody repertoire with the risk of autoantibody-mediated disease. Early in development, B cells randomly rearrange their immunoglobulin genes through VDJ recombination and encounter a series of tolerance checkpoints that serve to remove autoreactive B cell receptors (BCRs) from the repertoire. Strongly autoreactive immature B cells rearrange additional light chains to ‘edit’ their autoreactivity, and they ultimately undergo deletion if this is unsuccessful (Shlomchik, 2008). Yet, despite stringent counter-selection of autoreactivity, the mature follicular (Fo) B cell compartment retains cells reactive towards endogenous antigens (Wardemann et al., 2003; Zikherman et al., 2012). How these cells are restrained from mounting autoimmune responses is not fully understood.

We previously described a BAC Tg reporter mouse (Nur77-eGFP) in which GFP expression is under the control of the regulatory region of Nr4a1, an immediate early gene rapidly induced by antigen receptor signaling (Mittelstadt and DeFranco, 1993; Winoto and Littman, 2002). We showed that Nur77-eGFP expression in naïve B cells is proportional to strength of antigenic
**eLife digest** To defend an organism against invaders such as viruses and bacteria, cells of the immune system need to recognize and respond to foreign microbes. However, these immune cells must also avoid attacking ‘self’ – for example, the healthy tissues of the body – as this could lead to autoimmune disease.

B cells are a type of immune cell that is essential in order to produce antibodies, protective proteins that can identify and defend against a broad range of germs: in addition, certain antibodies can also recognize ‘self’. When a B cell first develops, it places its antibody on its surface and uses this protein as a receptor (termed ‘B cell receptor’) to sense its surroundings.

Prior to mounting an immune response, B cells carry two closely related versions of the B cell receptor on their surface: IgM and IgD. Both IgM and IgD perform many of the same roles and can largely substitute for one another. However, B cells that recognize ‘self’ decrease their levels of IgM but keep high amounts of IgD on their surface. It is unclear why this is the case, but one possibility is that IgM and IgD may see ‘self’ differently.

To investigate this, Noviski et al. used mice with B cells that only carry either IgM or IgD, and tracked how these cells reacted to molecules from ‘self’ and foreign origins. IgM-only B cells reacted more strongly to ‘self’ molecules than IgD-only cells, which suggests that IgM is more sensitive to ‘self’ than IgD. In fact, in mice which are at risk for an autoimmune disease similar to lupus, deleting the IgM receptor prevented antibodies against ‘self’ from being produced. Therefore, reducing the amount of IgM receptors may be a way to keep B cells that are reactive against ‘self’ from inappropriately attacking the host. Meanwhile, the IgD receptor still allows B cells to mount protective antibody responses against foreign microbes.

Future studies are necessary to determine whether these differences between IgM and IgD also exist in humans. If this is the case, blocking the IgM receptor could become a new kind of treatment for certain autoimmune diseases.

---

stimulation and consequently to autoreactivity (Zikherman et al., 2012). The most prominent characteristic of GFP<sup>hi</sup> reporter B cells is decreased surface IgM BCR relative to GFP<sup>lo</sup> cells. Goodnow and colleagues first suggested that IgM downregulation may mark autoreactive B cells in the normal mature repertoire shortly after they reported selective downregulation of IgM in the IgHEL (hen egg lysozyme) BCR Tg/soluble HEL Tg model system of B cell autoreactivity (Goodnow et al., 1988; Goodnow et al., 1989). Indeed, multiple studies in mice and humans have identified naturally occurring IgD<sup>+</sup>IgM<sup>lo</sup> cells as autoreactive and ‘anergic’ or functionally unresponsive (Duty et al., 2009; Kirchenbaum et al., 2014; Quách et al., 2011; Zikherman et al., 2012). These results corroborate observations with several BCR transgenic model systems (Cambier et al., 2007). However, whether or how IgM downregulation might constrain autoreactivity remains unclear because naturally-occurring autoreactive B cells maintain high expression of the IgD BCR isotype (Zikherman et al., 2012).

IgM and IgD are splice isoforms of a common precursor heavy chain mRNA (Moore et al., 1981). While they differ in their Fc domains, both BCR isotypes contain the same antigen-binding domain, as well as identical 3-amino acid cytoplasmic tails, and they pair with Igα/β in order to initiate the canonical BCR signaling cascade (Blum et al., 1993; Radaev et al., 2010). However, the expression pattern of the isoforms differs; IgM expression begins as soon as heavy and light chains recombine early in B cell development, and persists until class switch recombination occurs following B cell activation (Chen and Cerutti, 2010). IgD is uniquely co-expressed with IgM during a narrow developmental window on late transitional and mature naïve Fo B cells as a result of alternate splicing regulated by the zinc-finger protein ZFP318 (Enders et al., 2014; Pioli et al., 2014). This suggests that IgD may play a critical role specifically in mature naïve B cells. Initial characterization of IgM- and IgD-deficient mice revealed only mild phenotypes and substantial redundancy; each isotype could mediate B cell development, initiate antibody responses to T-dependent and -independent immunization, and induce normal levels of steady-state serum IgG (Lutz et al., 1998; Nitschke et al., 1993; Roes and Rajewsky, 1993). This is consistent with prior studies in BCR
transgenic model systems demonstrating that each isotype alone can mediate B cell development, deletion, and activation (Brink et al., 1992).

IgM and IgD differ structurally; IgD has a much longer, flexible hinge region linking its Fab and Fc regions than IgM does (Chen and Cerutti, 2010). Recently, Ubelhart, Jumaa, and colleagues demonstrated that a short and inflexible hinge confers upon IgM the unique capacity to signal in response to monovalent antigens, while both isotypes can respond to multivalent antigens (Ubelhart et al., 2015). However, the Goodnow lab subsequently showed that IgHEL Tg splenic B cells expressing either the IgD or IgM BCR exclusively could mobilize calcium in response to soluble HEL antigen in vitro, and each isotype can mediate a common gene expression program characteristic of anergy in vivo (Sabouri et al., 2016). Therefore, it remains unclear whether IgM and IgD BCRs expressed in an unrestricted B cell repertoire differentially sense bona fide endogenous antigens in vivo, particularly as the identity and nature of such antigens is largely unknown and not restricted to soluble monovalent antigens. For example, 5–10% of circulating naïve B cells in healthy humans express the well-characterized unmutated and autoreactive human heavy chain V-segment IGHV4-34, and these cells exhibit anergy, selective IgM downregulation, and recognize cell-surface antigens on erythrocytes and B cells in vivo (Quách et al., 2011; Reed et al., 2016).

We and others previously hypothesized that downregulation of IgM on Fo B cells might serve to restrain their response to endogenous antigen. Conversely, high expression of IgD on these cells might play a ‘tolerogenic’ role (Zikherman et al., 2012). To determine how IgM and IgD differentially regulate B cell responses to endogenous antigens, we generated Nur77-eGFP reporter mice deficient for either IgM or IgD (Lutz et al., 1998; Nitschke et al., 1993). Using this reporter of antigen-dependent signaling, we show that IgD is less sensitive than IgM to bona fide endogenous antigens in vivo despite higher surface expression and robust responsiveness to receptor ligation in vitro. Indeed, marginal zone (MZ) and B1a cells that express IgD but lack IgM induce less Nur77-eGFP than WT, and this is not attributable to repertoire differences. To further support these observations, we examine a series of cell fate decisions for which in vivo BCR signaling requirements have been previously defined. We show that IgD drives a pattern of development consistent with reduced endogenous antigen recognition, favoring MZ B cell fate and disfavoring B1a cell fate. Similarly, IgD alone is less efficient than IgM at driving SLPC expansion in response to endogenous antigens, a process that requires robust BCR signaling. However, IgD is sufficient for germinal center (GC) B cell differentiation. Our data suggest that reduced endogenous antigen sensing (i.e. signal transduction in response to antigen binding) by the IgD BCR isotype, shunts autoreactive IgD$^{hi}$ IgM$^{lo}$ Fo B cells away from differentiation into SLPCs. We propose that predominant IgD expression maintains the quiescence of autoreactive B cells in response to chronic endogenous antigen stimulation, and limits autoantibody secretion in the context of rapid immune responses.

## Results

**Endogenous antigen is both necessary and sufficient for expression of Nur77-eGFP reporter in B cells in vivo**

We previously showed that antigen recognition was both necessary and sufficient for Nur77-eGFP reporter expression by B cells in vivo (Figure 1A)(Zikherman et al., 2012). Thus, reporter expression reflects endogenous antigen recognition in vivo. Conversely, under steady-state conditions in vivo, the Nur77-eGFP reporter does not reflect signaling through other receptors expressed in B cells; indeed, loss of either CD40, or TLR3, 7, and 9 signaling has no effect on reporter expression in B cells in vivo (Figure 1—figure supplement 1A). Moreover, neither BAFF, nor IL-4, nor CXCR4-dependent signaling can regulate reporter expression in vitro (Figure 1—figure supplement 1B–C) (Zikherman et al., 2012). To further confirm that Nur77 expression in naïve B cells under steady state conditions is not regulated by microbial stimulation of pattern recognition receptors (e.g. TLRs 1, 2, 4, 6, and the TLR-4-like molecule RP105), we studied mice raised under either germ-free conditions or conventional specific-pathogen-free conditions. We observed no induction of endogenous Nur77 protein in splenic B cells or endogenous Nr4a1 transcript in splenocytes in the presence of commensal flora (Figure 1—figure supplement 1D,E). Moreover, MyD88-deficient and MyD88-sufficient splenocytes and peritoneal B1a cells express comparable amounts of endogenous Nr4a1 transcript and protein respectively under steady state conditions (Figure 1—figure supplement 1F,G).
Figure 1. IgD expression enables a dynamic range of IgM responsiveness. (A) GFP expression in mature Fo splenic B cells (CD19+CD23+CD93−) from Nur77-eGFP BAC Tg reporter mice with either a wild-type BCR repertoire (left), or harboring IgHEL Tg specific for the cognate antigen HEL (hen egg lysozyme) in the absence (middle), or presence (right) of endogenous cognate antigen driven by soluble HEL Tg. WT Fo B cells lacking GFP reporter are included for reference (gray shaded histograms). (B) Surface IgM and IgD expression in splenic Fo B cells from WT, IgM−/−, and IgD−/− mice expressing the Nur77-eGFP reporter. (C) Splenocytes from WT, IgM−/−, and IgD−/− mice were loaded with Indo-1 and stimulated with 2.5 μg/mL of F(ab')2 anti-IgM or 1:400 anti-IgD. Fo B cells with the highest 20% and lowest 20% Nur77-eGFP expression are compared. (D) Representative histograms and quantification of surface Igk expression in IgM−/− and IgD−/− Fo B cells normalized to WT. (E) Representative histograms and quantification of Nur77-eGFP expression in IgM−/− and IgD−/− Fo B cells normalized to WT. (F) Median surface Igk expression of WT, IgM−/−, and IgD−/− Fo B cells was calculated for 200 bins of equal width across the Nur77-eGFP spectrum. For (A), (B) and (F), data are representative of at least n = 4 independent experiments. For (C), n = 3 independent experiments for anti-IgM and n = 2 independent experiments for anti-IgD. For (D) and (E), n = 7 and n = 4, respectively, WT, IgM−/−, and IgD−/− mice. Welch’s t test was used to calculate p values, and mean ±SEM is displayed. ***p<0.001.

DOI: https://doi.org/10.7554/eLife.35074.003

The following source data and figure supplements are available for figure 1:

Source data 1. Numerical data corresponding to receptor and Nur77 reporter, protein and transcript levels in Figure 1D–F and Figure 1—figure supplement 1D-G, 2B-E.

Figure 1 continued on next page
Taken together, these data demonstrate that Nur77-eGFP expression in B cells under steady-state conditions in vivo is a specific readout of antigen-dependent signaling through the BCR (Table 1). We therefore sought to take advantage of the Nur77-eGFP reporter in order to probe the responsiveness of a diverse BCR repertoire of mature B cells expressing either IgM or IgD alone to the vast range of endogenous antigens they may encounter in vivo.

Table 1. Nur77-eGFP is a specific reporter of antigen-dependent signaling in vivo.

| Conclusion                          | Stimulus/ perturbation | Pathway | Readout                     | Cell type          | References                                                                 |
|-------------------------------------|------------------------|---------|-----------------------------|--------------------|-----------------------------------------------------------------------------|
| Does not modulate Nur77 at steady state in vivo | CD40L−/−              | CD40    | Nur77-eGFP                  | B cells            | Manuscript Figure 1-figure supplement 1A                                    |
|                                     |                       |         |                             |                    |                                                                             |
|                                     | TLR7−/−               | TLR7    | Nur77-eGFP                  | B cells            | Manuscript Figure 1-figure supplement 1A                                    |
|                                     |                       |         |                             |                    |                                                                             |
|                                     | Unr93b1−/−/−           | UnR377/9| Nur77-eGFP                  | B cells            | Manuscript Figure 1-figure supplement 1A                                    |
|                                     |                       |         |                             |                    |                                                                             |
|                                     | MyD88−/−/−             | MyD88   | Endog. Nur77 protein/transcript | PerC B1a cells/spleen | Manuscript Figure 1-figure supplement 1F,G                                |
|                                     |                       |         |                             |                    |                                                                             |
| Germ-free mice                      |                       | MyD88/ TRIF | Endog. Nur77 protein/transcript | Splenic B cells/spleen | Manuscript Figure 1-figure supplement 1D,E                                   |
|                                     |                       |         |                             |                    |                                                                             |
| Const. act. STATS                   | Jak/Stat              | Nur77-eGFP |                             | Thymocytes         | Moran et al. JEM 2011, Figure 8.                                             |

Does not induce Nur77 in vitro

|                                              |                      |         |                             |                    |                                                                            |
|                                              | BAFF                  | BAFFR   | Nur77-eGFP                  | B cells            | Zikherman et al. (2012): Figure S1G                                       |
|                                              | IL-4                  | Jak/Stat | Nur77-eGFP                  | B cells            | Manuscript Figure 1-figure supplement 1B                                 |
|                                              | IL-2, IL-15           | Jak/Stat | Nur77-eGFP                  | CD8 (IL-2, 15), CD4 (IL-2) | Au-Yeung et al. JI 2017, Figures S1A, 3C, 4A                             |
|                                              | CXCL12/ SDF-1         | CXCR4   | Nur77-eGFP                  | B cells            | Manuscript Figure 1-figure supplement 1C                                 |

Induces Nur77 in vitro but does not require IgM or IgD specifically

|                                              |                      |         |                             |                    |                                                                            |
|                                              | LPS                   | TLR4, R150 | Nur77-eGFP                  | B cells            | Zikherman et al. (2012): Figure S1G, Manuscript Figure 1—figure supplement 1A |
|                                              | Cpg                   | TLR9    | Nur77-eGFP                  | B cells            | Zikherman et al. (2012), Figure S1G, Manuscript Figure 1—figure supplement 1A |
|                                              | Pam3CSK4              | TLR1/2  | Nur77-eGFP                  | B cells            | Manuscript Figure 1—figure supplement 1A                                  |
|                                              | Anti-Igκ              | BCR     | Nur77-eGFP                  | B cells            | Manuscript Figure 2                                                        |

Modulates pathway at steady state in vivo

|                                              |                      |         |                             |                    |                                                                            |
|                                              | IgHEL Tg              | Antigen/ BCR | Nur77-eGFP                  | B cells            | Zikherman et al. (2012), Figure 3B,C, Manuscript Figure 1A               |
|                                              | IgHEL BCR Tg/sHEL Ag  | Antigen/ BCR | Nur77-eGFP                  | B cells            | Zikherman et al. (2012), Figure 3B,C, Manuscript Figure 1A               |
|                                              | Lyn−/−                | BCR via ITIMs | Nur77-eGFP                  | B cells            | Manuscript Figure 5—figure supplement 3A                                 |
|                                              | CD45 allelic series   | BCR via SFKs | Nur77-eGFP                  | B cells            | Zikherman et al. (2012), Figure 3A,B                                      |
Figure 2. IgD signals strongly in vitro but weakly in vivo. (A) Median intracellular pErk in splenic CD23+ B cells stimulated with anti-Igk for 15 min. (B) Erk phosphorylation kinetics in splenic CD23+ B cells stimulated with 15 μg/mL anti-Igk. (C) Splenocytes from IgM−/− and IgD−/− mice were loaded with Indo-1 and stimulated with 2.5 or 5 μg/mL anti-Igk. B220+/CD23+/CD93− Fo B cells are compared. (D) CD86 induction in CD23+ IgM−/− and IgD−/− splenocytes stimulated with anti-Igk for 18 hr. (E) Summary data for CD86 MFI in (D). (F) Nur77-eGFP induction in cells from (D). (G) Nur77-eGFP in cells from (D) incubated with medium alone (0 μg/mL anti-Igk). (H) Representative histograms and summary data for MHC-II induction in unstimulated cells from (D). (I) Basal calcium in unstimulated IgM−/− and IgD−/− Fo B cells was calculated by normalizing the geometric mean of [Indo-1(violet)/Indo-1(blue)] to WT B cells in the same experiment. For (A), signaling in cells from n = 2 IgM−/− and IgD−/− mice is displayed, and results for 1.5, 3, and 15 μg/mL of anti-Igk were replicated in n = 3 independent experiments. Data in (B) was compiled from n = 3 independent experiments with n = 3 mice of each genotype in each experiment. Data in (C) are representative of n = 4 independent experiments for 5 μg/mL and n = 2 independent experiments for 2.5 μg/mL. For (D-H), values were calculated for splenocytes from n = 3 mice of each genotype. For (I), basal calcium ratios from n = 6 independent experiments are compiled. Welch’s t test was used to calculate p values, and mean ±SEM is displayed. *p<0.05, **p<0.01, ***p<0.001.

DOI: https://doi.org/10.7554/eLife.35074.011

The following source data and figure supplement are available for figure 2:

Source data 1. Numerical data corresponding to Figure 2A and B, E-I, and Figure 2—figure supplement 1A.
DOI: https://doi.org/10.7554/eLife.35074.013

Source data 2. Numerical data corresponding to basal calcium in Figure 2I.
DOI: https://doi.org/10.7554/eLife.35074.014

Figure supplement 1. S6 and calcium signaling in IgM−/− and IgD−/− B cells.
DOI: https://doi.org/10.7554/eLife.35074.012
Dual expression of IgM and IgD BCRs is required to establish a broad dynamic range of BCR responsiveness across the repertoire

Surface IgM, but not IgD, expression is inversely correlated with endogenous antigen recognition across a diverse repertoire of mature naïve follicular (Fo) B cells, such that B cells reactive to endogenous antigens express high levels of IgD and low levels of IgM on their surface (Figure 1B) (Zikherman et al., 2012). The variation in surface IgM expression across the B cell repertoire is profound, spanning a 100-fold range. However, because IgD is expressed at high and invariant levels in all WT naïve Fo B cells, total surface BCR, unlike IgM, has little dynamic range across the WT repertoire (Figure 1—figure supplement 2A).

To explore how IgM and IgD differentially regulate B cells reactive to endogenous antigens, we generated Nur77-eGFP mice deficient for either IgM or IgD (Lutz et al., 1998; Nitschke et al., 1993). In IgM−/− mice, all B cells express IgD alone prior to class switch recombination (CSR), and in IgD−/− mice, all B cells express IgM alone prior to CSR. We observed that IgM is still downregulated...
on IgD\textsuperscript{−/−} GFP\textsuperscript{hi} Fo B cells, but the dynamic range of IgM expression is highly restricted relative to the broad range observed on WT cells (Figure 1B).

We previously showed that IgM down-modulation on GFP\textsuperscript{hi} reporter B cells largely accounts for impaired signaling through IgM (Figure 1C) (Zikherman et al., 2012). However, the narrow dynamic range of IgM on IgD-deficient cells renders reporter B cells unable to fine-tune signaling through the IgM BCR across the GFP repertoire (Figure 1C). Furthermore, IgD-mediated signaling is not altered across the GFP repertoire in the presence or absence of IgM (Figure 1C). As a result, reduced responsiveness of GFP\textsuperscript{hi} B cells is most profound in B cells that express the IgM isotype in the presence of IgD. This suggests that IgD expression may be necessary to establish and/or maintain a broad and functionally dynamic range of surface IgM expression across the B cell repertoire. This is consistent with a previously proposed survival function for the IgD BCR (Roes and Rajewsky, 1993; Sabouri et al., 2016).

**IgM\textsuperscript{−/−} follicular B cells express more surface BCR than IgD\textsuperscript{−/−} follicular B cells, but similar Nur77-eGFP**

Deletion of either the IgM or the IgD BCR isotype results in compensatory upregulation of the remaining isotype. This may be due in part to a change in competition for pairing with Ig\alpha/\beta heterodimers, which is essential for trafficking of IgM to the cell surface (Hombach et al., 1990; Sabouri et al., 2016). IgM\textsuperscript{−/−} B cells express about twice as much surface BCR as IgD\textsuperscript{−/−} B cells, as measured by surface anti-light chain staining (Figure 1D and Figure 1—figure supplement 2B–E). Nevertheless, distribution of Nur77-eGFP expression across the naive B cell repertoire is nearly identical in IgM\textsuperscript{−/−} and IgD\textsuperscript{−/−} Fo B cells (Figure 1E). Further, at every level of Nur77-eGFP, cells that express IgD alone require more surface BCR to drive an equivalent amount of GFP compared to cells that express IgM alone (Figure 1F). This suggests that on a per-receptor basis, IgD BCR may be less efficient at inducing Nur77-eGFP in response to endogenous antigens. Importantly, this is not attributable to differential dependence upon IgM or IgD expression for signaling via CXCR4 or downstream of canonical TLR ligands (Figure 1—figure supplement 1C, Figure 1—figure supplement 3A).

**IgD BCR crosslinking induces robust signaling in vitro**

Because IgD drives less Nur77-eGFP per receptor than IgM in vivo, we wanted to determine whether there were defects in signal transduction downstream of IgD. To mimic antigen binding to the membrane-distal end of the BCR and allow for direct comparison between the isotypes, we stimulated IgD-only (IgM\textsuperscript{−/−}) and IgM-only (IgD\textsuperscript{−/−}) cells with anti-Igκ and compared downstream signaling. BCR ligation in IgD-only B cells induced equivalent amounts of Erk phosphorylation relative to IgM-only B cells (Figure 2A), and there were no gross differences in pErk kinetics (Figure 2B). Additionally, IgD-only cells induced more robust intracellular calcium increase and S6 phosphorylation than IgM-only cells (Figure 2C and Figure 2—figure supplement 1A). This was not due to differential effects of the Fc portion of the stimulatory antibody on IgM-only and IgD-only B cells as anti-Igκ-F(ab\textsuperscript{'})\textsubscript{2} and anti-Igκ stimulation produced identical signaling (Figure 2—figure supplement 1B).

**IgD BCRs sense endogenous antigens less efficiently than IgM BCRs**

Due in part to increased surface receptor expression, IgD-only B cells induce comparable Erk phosphorylation and enhanced calcium mobilization relative to IgM-only B cells stimulated with anti-Igκ. As a result, we observe significantly more CD86 and Nur77-eGFP induction in IgD-only B cells after 18 hr of anti-Igκ stimulation in vitro (Figure 2D–F). However, IgD-only cells induced less Nur77-eGFP and MHC-II upregulation when cultured in the absence of exogenous stimulus (Figure 2G and H). This discrepancy suggests that despite increased receptor expression and efficient coupling to downstream signaling machinery, residual endogenous antigens occupying the IgD BCR are less efficient at inducing signaling ex vivo. Consistent with this hypothesis, basal calcium analyzed immediately ex vivo is depressed in cells that express only IgD (Figure 2I). These data suggest that while signal transduction downstream of the IgD BCR is robust in vitro, IgD responds less efficiently than IgM to the relevant antigens it encounters in vivo.
Reduced endogenous antigen sensing by IgD BCR in innate-like B cells

While IgD-only and IgM-only Fo B cells express comparable levels of Nur77-eGFP (Figure 1E), we suspected that competitive pressures for survival might constrain the acceptable range of BCR signaling among mature Fo B cells. We further speculated that compensatory mechanisms such as altered surface receptor and altered BCR repertoire might fine tune how much signaling Fo B cells experience in vivo in order to lie within this range. In contrast to Fo B cells, IgD-only marginal zone (MZ) and B1a cells expressed significantly less Nur77-eGFP than WT cells despite higher levels of surface BCR (Figure 3A, Figure 1—figure supplement 2B–E). To determine whether this difference was due to isotype or altered BCR repertoire, we probed GFP expression in B1a cells specific for phosphatidylcholine (PtC), an endogenous antigen exposed on the surface of dying cells that is thought to select developing B cells into the B1a compartment (Baumgarth, 2011). We found a large difference in GFP even among B1a cells with a common specificity, and this occurs in spite of high surface PtC binding in IgD-only B1a cells (Figure 3B and C).

We took an independent and complementary approach to address the same question in MZ B cells; we crossed IgM−/− and IgD−/− reporter mice to a genetic background that drives over-expression of the B cell survival factor BAFF (Gavin et al., 2005). BAFF overexpression ‘unrestricts’ the BCR repertoire by removing competition for survival, thereby reducing both positive and negative selection pressures and permitting cells with either insufficient or excessive BCR signaling to persist in the repertoire, resulting in a massively expanded MZ compartment (Stadanlick and Cancro, 2008). Importantly, BAFF does not directly regulate reporter GFP expression, and therefore GFP reflects endogenous antigen stimulation on this genetic background (Zikherman et al., 2012). In BAFF Tg mice, IgD-only MZ cells expressed much less GFP than those expressing IgM alone (Figure 3D and E). This was not explained by differences in surface receptor levels between these populations as they are comparable on this genetic background (Figure 3—figure supplement 1A). Indeed, IgD-only cells with low GFP and IgM-only cells with high GFP appear to be preferentially rescued in mice with excess BAFF, suggesting that distinct BCR repertoires, far from accounting for GFP differences between IgM-only and IgD-only MZ cells, actually obscure these differences. Conversely, either ‘fixing’ or unrestricting the BCR repertoire unmasks impaired GFP upregulation by IgD relative to IgM.

As a result of allelic exclusion of the heavy chain locus during B cell development, IgM−/− heterozygous mice develop two genetically distinct sets of B cells in which half express only IgD and the other half express both IgM and IgD. We exploited this property to confirm that the Nur77-eGFP difference in the MZ and B1a compartments is cell intrinsic and not a consequence of the presence or absence of serum IgM (Figure 3—figure supplement 1B).

Since IgM−/− and IgD−/− mice were generated on the Balb/c and 129 genetic backgrounds respectively, their germline VDJ loci are different from that of C57BL/6 mice to which they have been back-crossed. Throughout our study, we have validated our findings in either Balb/c-B6 F1 mice or IgH−/− heterozygous mice, which have two sets of B cells with identical IgM and IgD isotype expression but distinct germline VDJ loci. We took this approach to confirm that differences in MZ GFP were due to BCR isotype and not VDJ locus (Figure 3—figure supplement 1C).

Cell-intrinsic skewing of B cell development by the IgM and IgD BCRs

Generation of the B1a compartment requires endogenous antigen recognition and strong BCR signaling, while the opposite is true for MZ B cells (Figure 4—figure supplement 1A) (Cariappa and Pillai, 2002; Casola et al., 2004). Indeed, B1a cells are modestly reduced in IgM-deficient mice, while MZ B cells are modestly increased (Figure 4—figure supplement 1B–C). Because serum IgM deficiency leads to increased B1a numbers, we assessed B1a and MZ B cell development in a competitive setting to isolate the cell-intrinsic effects of IgM and IgD BCRs (Boes et al., 1998). Analogous to the IgM−/− mice described above, IgM−/− IgD−/− heterozygous mice develop two genetically distinct sets of B cells in which half express only IgD and the other half express only IgM (Figure 4A). Although IgD-only B cells can partially populate the B1a compartment in the absence of competition (Lutz et al., 1998; Übelhart et al., 2015), IgD-only cells are virtually excluded from this compartment in a competitive setting (Figure 4B). Indeed, this parallels the loss of PtC-binding IgD-only peritoneal B cells observed in competition with wild type cells (Übelhart et al., 2015). In contrast, IgD-only B cells preferentially populate the MZ B cell compartment in competition with
IgM-only B cells (Figure 4B). These data are consistent with a signal strength model of B1a/MZ B cell development (Figure 4—figure supplement 1A), and this suggests that in vivo signaling, antigen recognition, or both are reduced in IgD-only B cells. These differences in signaling could in turn modulate the generation and/or survival of IgD-only B1a and MZ B cells.

We sought to determine whether skewed development of B cell lineages was driven primarily by properties of IgD, IgM, or both by comparing development of B cell populations in IgM<sup>−/−</sup> IgD<sup>−/−</sup>,
IgM+/−, and IgD+/− mice (Figure 4C–4E). We conclude that skewing of MZ and B1a fates is primarily attributable to lack of IgM expression on IgD-only cells rather than lack of IgD expression on IgM-only cells because we observe little skewing in IgD+/− mice (Figure 4E). Further, the competitive advantage of IgD-only cells in the marginal zone niche is reduced by BAFF over-expression, consistent with loosening of competitive selection pressures (Figure 4F).

IgM-only B cells exhibit a disadvantage in the mature Fo compartment relative to IgD-only B cells (Figure 4C). We find that absence of IgD rather than excess IgM expression accounts for some of this disadvantage as WT and IgD-only cells compete equally well in this compartment (Figure 4D). This may reflect impaired positive selection or survival in absence of IgD. Indeed, similar to our observations, a disadvantage for Fo B cells lacking IgD was observed in IgD+/− mice previously (Roes and Rajewsky, 1993). As with differences in Nur77-eGFP expression, we confirmed that the developmental fates of IgM-only and IgD-only cells were due to BCR isotype and not VDJ locus (Figure 4—figure supplement 1D).

Either IgD or IgM BCR is sufficient to mediate polyclonal B cell activation and germinal center differentiation in Lyn−/− mice

Mice deficient for either IgM or IgD can mount T-independent and T-dependent immune responses to model antigens (Lutz et al., 1998; Nitschke et al., 1993; Roes and Rajewsky, 1993). However, endogenous antigens may have unique properties that are absent in model antigen systems. To test whether each BCR isotype was competent to mediate autoimmune responses to endogenous antigens in lupus-prone mice, we generated IgM+/− and IgD+/− mice on the Lyn−/− background (Chan et al., 1997). The Src family kinase Lyn is essential to mediate ITIM-dependent inhibitory signals in B cells and myeloid cells (Scapini et al., 2009; Xu et al., 2005). Lyn−/− mice consequently develop a spontaneous lupus-like disease characterized by anti-DNA antibodies and nephritis on the C57BL/6 genetic background (Chan et al., 1997; Hibbs et al., 1995; Nishizumi et al., 1995). It has been shown that both B-cell-specific MyD88 expression and T cells are essential for IgG2a/c anti-dsDNA autoantibody production in Lyn−/− mice, and conditional deletion of Lyn in B cells is sufficient for autoimmunity (Hua et al., 2014; Lamagna et al., 2014).

Secreted natural IgM is thought to play important homeostatic functions that repress autoimmunity, particularly clearance of dead cell debris (Boes et al., 2000; Manson et al., 2005). By performing our analysis in mice with wild type and IgM-only or IgD-only B cells in a common milieu (IgM+/− Lyn−/− and IgD+/− Lyn−/− mice), we could control for this and isolate the B cell-intrinsic effects of the IgM and IgD BCRs. Importantly, precursor Fo B cells are present at roughly equal ratios from WT and IgM-only or IgD-only loci in these mice, and this is unaffected by VDJ background (Figure 5—figure supplement 1A–C). Moreover, Lyn−/− B cells expressing either IgM or IgD alone exhibit enhanced BCR signaling in vitro relative to Lyn+/+ B cells, suggesting that neither isotype is uniquely coupled to ITIM-containing receptors (Figure 5—figure supplement 2A–B).

Polyclonal B cell activation in Lyn−/− mice precedes and is genetically separable from autoantibody production; it is driven by B cell-intrinsic loss of Lyn, is thought to result from enhanced BCR signaling, and is independent of MyD88 expression (Hua et al., 2014; Lamagna et al., 2014). Indeed, Lyn−/− reporter B cells have elevated Nur77-eGFP expression consistent with enhanced BCR signal transduction in vivo (Figure 5—figure supplement 3A). We had expected that activation of IgD-only Lyn−/− B cells might be impaired due to reduced sensing of endogenous antigens, but neither CD86 nor CD69 upregulation were significantly different on WT and IgD-only B cells in the absence of Lyn (Figure 5A). This implies that both BCRs can provide sufficient signals to drive polyclonal activation by endogenous antigens.

Although GC fate is disfavored relative to SLPC fate in Lyn−/− mice, GCs do arise spontaneously with time (Hibbs et al., 1995; Hua et al., 2014). We found that both IgD-only and IgM-only cells in Lyn-deficient mice made comparable contributions to the GC compartment in competition with wild type B cells, independent of VDJ background (Figure 5B and Figure 5—figure supplement 3B–C). We propose that endogenous antigen sensing by IgD, while normally dampened, is sufficient to drive both polyclonal activation and GC differentiation on the Lyn−/− background. This further implies that antigen capture by IgD and presentation on MHC-II is robust enough to recruit adequate T cell help to support these cell fates.
Figure 5. IgD can drive polyclonal activation and germinal center entry, but not anti-dsDNA IgG2a production, in Lyn−/− mice. (A) Surface CD69 and CD86 expression on CD23+ splenic B cells from each Ig locus in IgM+/+ mice on Lyn+/+ and Lyn−/− backgrounds. (B) Percentage of unswitched germinal center (CD19+ Fashigh GL-7high IgM/IgD+) B cells from each Ig locus in IgM+/+ and IgD+/+ mice on the Lyn−/− background. (C) Anti-dsDNA IgG2a titers from each Ig locus in IgM+/+ Lyn+/+ mice were calculated by ELISA using pooled IgHα/β autoimmune serum with high-titer autoantibodies from each locus as a reference (titer set at 1000). Each color represents a single mouse tracked over time. (D) Anti-dsDNA IgG2a titers in IgD+/+ Lyn−/− mice were calculated as in (C). (E) Paired anti-dsDNA titers from each locus in individual IgM+/+ Lyn−/− mice from (C) with additional mice from 24 weeks to 12 months. (F) Paired anti-dsDNA titers from each locus in IgD+/+ Lyn−/− mice from (D). (G) Ratio of anti-dsDNA IgG2a[a] to IgG2a[b] from all samples in (E) and (F) with an anti-dsDNA IgG2a titer >250 from either locus, cutoff defined by titers in young WT mice. For (A), n = 4 IgM+/+ Lyn−/− mice are compared to a reference IgM+/+ Lyn+/+ mouse. Qualitatively similar results were obtained in two independent experiments. For (B) n = 5–6 mice of each genotype were analyzed. For (C) and (D), n = 9 and n = 12 mice were tracked. For (G), n = 36 IgM+/+ Lyn−/− and n = 39 IgD+/+ Lyn−/− anti-dsDNA IgG2a+ samples were compared. Welch’s t test was used to calculate p values, and mean ±SEM is displayed. **p<0.01.

DOI: https://doi.org/10.7554/eLife.35074.024

The following source data and figure supplements are available for figure 5:

Source data 1. Numerical data corresponding to Figure 5A-G, Figure 5—figure supplement 1B-C, 3C-E.

DOI: https://doi.org/10.7554/eLife.35074.028

Figure supplement 1. Splenic B cell subsets in IgHα/β, IgM+/+, and IgD+/+ Lyn−/− mice.

DOI: https://doi.org/10.7554/eLife.35074.025

Figure supplement 2. Signaling in IgM+/+ and IgD+/+ Lyn−/− B cells.

DOI: https://doi.org/10.7554/eLife.35074.026

Figure supplement 3. Nur77-eGFP in Lyn−/− B cells and the role of BCR allotype in Lyn−/− phenotypes.

DOI: https://doi.org/10.7554/eLife.35074.027

Noviski et al. eLife 2018;7:e35074. DOI: https://doi.org/10.7554/eLife.35074

12 of 29

Research article
Immunology and Inflammation
IgM BCR is required to drive dsDNA antibody production in Lyn⁻/⁻ mice

IgM- and IgD-deficient B cells express BCR heavy chain allotype [a] (IgHᵃ), and their secreted antibodies can be differentiated from WT B6 antibodies (IgHᵇ) even after isotype switching (e.g. IgG₂a[a] vs. IgG₂a[b] – also referred to as IgG₂c). Allotype-specific antibodies have been previously used in the context of lupus mouse models to track autoantibodies generated by B cells of distinct genetic origin (Mills et al., 2015; Pisitkun et al., 2006). We took an analogous approach to assess IgG₂a/c anti-dsDNA autoantibodies emanating from each genetic locus in IgM⁻/⁻, IgD⁻/⁻, and IgHᵃ⁻/ᵇ control mice deficient for Lyn. In order to compensate for reduced penetrance of autoantibody production in IgM⁻/⁻ Lyn⁻/⁻ mice, we collected serum from this genotype at time points beyond 24 weeks to increase the number of samples in which tolerance had been broken. While B cells expressing IgM (of either IgH locus) generated IgG₂a/c anti-dsDNA, IgD-only B cells were relatively protected from generating anti-dsDNA antibodies, even at late time points (Figure 5C–G, Figure 5—figure supplement 3D–E). Importantly, this is attributable to BCR isotype and not VDJ locus (Figure 5—figure supplement 3D–E).

We noted that anti-dsDNA antibody titers fluctuated substantially over time in Lyn⁻/⁻ mice, in some cases dropping markedly over a four-week period (Figure 5C and D). Anti-dsDNA IgG autoantibodies in patients with systemic lupus erythematosus (SLE) similarly fluctuate over time – in contrast to other anti-nuclear specificities - and correlate with disease flares (Liu et al., 2011). Furthermore, unmutated germline BCRs from naïve B cells are recruited directly into the circulating plasmablast compartment during SLE flares (Tipton et al., 2015). Taken together, this suggests that anti-dsDNA antibodies in mice and humans are secreted at least in part by SLPCs emerging from an extra-follicular immune response, rather than long-lived plasma cells (LLPCs) that originate in GCs. Our data suggests that, in the absence of Lyn, the IgD BCR is sufficient to mediate B cell activation and GC entry, but the IgM BCR is essential to produce dsDNA-specific SLPCs.

IgM BCR is required for expansion of unswitched plasma cells in Lyn⁻/⁻ mice

In addition to stochastic generation of autoantibodies over time, Lyn⁻/⁻ mice exhibit a massive expansion of the splenic IgM plasma cell compartment that corresponds to a roughly 10-fold increase in serum IgM (Hibbs et al., 1995). While natural IgM is thought to be secreted by B1a-derived plasma cells (Baumgarth, 2011), elevated serum IgM in Lyn⁻/⁻ mice arises from the Fo B2 compartment since Lyn⁻/⁻ mice lack MZ B cells, and bone marrow chimeras lacking the B1a compartment reconstitute the hyper-IgM secretion phenotype (Luo et al., 2014). Moreover, while BCR signaling is prominently enhanced in Lyn⁻/⁻ B2 B cells, it is markedly dampened in Lyn⁻/⁻ B1a cells (Figure 6—figure supplement 1A) (Skrzypczynska et al., 2016).

IgM plasma cell expansion is temporally and genetically separable from autoimmunity in Lyn⁻/⁻ mice; this phenotype develops in mice as young as 7–10 weeks of age with 100% penetrance, is B-cell intrinsic, and is not dependent upon MyD88 expression (Hua et al., 2014; Infantino et al., 2014; Lamagna et al., 2014). A pathway involving Btk, Ets1, and Blimp-1 is thought to drive this phenotype. Ets1 inhibits plasma cell differentiation in part by antagonizing the key transcriptional regulator of plasma cell fate, Blimp-1 (John et al., 2008). Mice deficient for Ets1 display IgM plasma cell expansion, Ets1 levels are reduced in Lyn⁻/⁻ mice, and restoration of Ets1 expression normalizes IgM plasma cell numbers (Luo et al., 2014). Furthermore, reducing levels of Btk, a critical kinase that mediates BCR signaling, is sufficient to suppress IgM plasma cell expansion in Lyn⁻/⁻ mice, and Ets1 levels are concomitantly restored to normal levels in Btk⁻/⁻ Lyn⁻/⁻ mice (Gutierrez et al., 2010; Luo et al., 2014; Mayeux et al., 2015). Therefore, IgM plasma cell expansion in Lyn⁻/⁻ mice is driven by exaggerated Btk-dependent BCR stimulation of B2 B cells by endogenous antigens (Figure 6—figure supplement 2A). Indeed, enhanced BCR signaling has been shown to favor SLPC fate over GC differentiation in Lyn-sufficient mice as well (Chan et al., 2009; Nutt et al., 2015; Paus et al., 2006). We therefore wondered whether impaired endogenous antigen sensing by IgD influenced Ets1 expression and unswitched PC expansion in Lyn⁻/⁻ mice.

As previously shown, Lyn⁻/⁻ B cells downregulate Ets1 protein expression (Figure 6A) (Luo et al., 2014). However, Lyn-deficient B cells expressing only IgD did not do so, consistent with a reduced ability of IgD to transmit antigen-dependent signals in vivo (Figure 6A). As previously reported, we...
found that the frequency of plasma cells in the spleens of Lyn−/− mice was increased fourfold relative to Lyn+/+ mice, but the bone marrow plasma cell compartment size was relatively unaffected (Figure 6B–C) (Infantino et al., 2014). The increase in splenic plasma cells was attributable entirely to unswitched (IgM+) plasma cells (Figure 6C). However, unswitched plasma cell expansion was completely absent in IgM−/− Lyn−/− spleens (Figure 6C). This was reflected in steady-state serum antibody levels; while Lyn−/− mice have elevated serum IgM relative to WT mice, IgM−/− Lyn−/− mice did not have elevated serum IgD relative to IgM−/− mice (Figure 6D–E).

To confirm that resistance to unswitched plasma cell expansion was a cell-intrinsic feature of IgD-only Lyn−/− B cells, we assessed this phenotype in IgM−/− Lyn−/− mice. Similar to the non-competitive setting, IgD-only Lyn−/− cells did not contribute to an expansion in the unswitched plasma cell compartment (Figure 6F–G). This effect was due to isotype and not VDJ allele usage because both

Figure 6. Cell-intrinsic IgM expression is required for unswitched plasma cell expansion in Lyn−/− mice. (A) Representative blot and quantification of Ets1 and GAPDH protein in purified splenic B cells from WT, Lyn−/−, and IgM−/− Lyn−/− mice. (B) Composition of the CD138+ plasma cell compartments in the spleen and bone marrow of WT, Lyn−/−, and IgM−/− Lyn−/− mice was determined by intracellular staining of IgM, IgD, and IgA. (C) Percentages in (B) multiplied by the fraction of live cells positive for CD138 in each tissue. Unswitched cells are positive for either IgM or IgD. Statistics correspond to unswitched plasma cell percentages; differences in IgA+ cells were not significant. (D) Serum IgM in 16-week-old mice was quantified for B6.IgHa (WT) and Lyn−/− mice by ELISA. A sample from an IgM−/− mouse is shown for reference. (E) Serum IgD in 16-week-old mice was quantified for IgM−/− and IgM−/− Lyn−/− mice by ELISA. A sample from a WT mouse is shown for reference. (F) Gating scheme for quantifying the unswitched splenic plasma cell composition of IgM−/− Lyn−/− mice. (G) Percentage of unswitched splenic plasma cells (CD138+B220loIgM/IgD+) from each locus in IgM−/− and IgD−/− mice on the Lyn−/− background. For (B) and (C), figures are representative of n = 4–5 mice of each genotype. For (D), values from n = 3 WT and n = 4 Lyn−/− mice are averaged. For (E), values from n = 3 IgM−/− and n = 4 IgM−/− Lyn−/− mice are averaged. For (F) and (G), n = 4–5 mice of each genotype were used. Welch’s t test was used to calculate p values, and mean ± SEM is displayed. *p<0.05, **p<0.01, ***p<0.001.

DOI: https://doi.org/10.7554/eLife.35074.029

The following source data and figure supplements are available for figure 6:

Source data 1. Numerical data corresponding to Ets1 expression, plasma cell compartments, and serum IgM and IgD titers in Figure 6A-G.
DOI: https://doi.org/10.7554/eLife.35074.032

Source data 2. Numerical data corresponding to Ets1 expression in splenic B cells in Figure 6A.
DOI: https://doi.org/10.7554/eLife.35074.033

Source data 3. Numerical data corresponding to plasma cell compartments in Figure 6B–C.
DOI: https://doi.org/10.7554/eLife.35074.034

Figure supplement 1. BCR signaling in Lyn−/− peritoneal B cell subsets.
DOI: https://doi.org/10.7554/eLife.35074.030

Figure supplement 2. Lyn restrains unswitched plasma cell differentiation of follicular B cells.
DOI: https://doi.org/10.7554/eLife.35074.031
IgM BCR is required for efficient generation of short-lived IgG1+ plasma cells but is dispensable for GC B cell fate

IgD-only Lyr+/− Fo B cells are completely prevented from generating an expanded unswitched SLPC compartment in response to chronic endogenous antigen stimulation, but they are competent to enter the GC. To determine how this defect relates to responses towards exogenous model antigens, we sought to determine whether IgD-only Lyr+/− B cells exhibit skewing of cell fate in the context of a T-dependent response to a model antigen. To generate a robust polyclonal B cell response in which T cell help should not be limiting, we used the classic immunogen sheep RBCs. During this immune response, Fo B cells can either enter the germinal center or rapidly differentiate into IgG1+-SLPCs (Chan et al., 2009; Paus et al., 2006). We found that wild type, IgM+/−, and IgD−/− mice all produced extremely robust GC responses 5 days after SRBC injection, but B cells expressing IgD alone were unable to produce IgG1+-SLPCs at this time point (Figure 7A–D).

Since serum IgM is absent in IgM−/− mice and is known to enhance PC generation (Boes et al., 1998), we wanted to assess the cell-intrinsic effect of IgD and IgM BCRs on the immune response to SRBCs. To do so, we immunized IgM−/− mice in which half of Fo B cells express IgD alone and half express both IgM and IgD. We could track the relative contribution of these two cell populations to the GC response because the bulk of GC B cells have not yet isotype-switched and express surface IgM or IgD. Both cell types made a robust contribution to the germinal center response (Figure 7E). Next we tracked the generation of IgG1+ PC by detecting allotype [a] or allotype [b] IgG1. In contrast to the GC response, IgD-only B cells were significantly disfavored in this compartment, although the defect was less severe than that observed in IgM−/− mice, which lack serum IgM (Figure 7F). To control for differences in the VDJ locus, we performed this experiment using IgHα/β mice and observed no significant differences between allotypes, implying that BCR isotypes rather than VDJ locus accounted for our observations (Figure 7—figure supplement 1A–B).

In contrast to impaired IgG1 SLPC responses by IgD-only B cells, we observed that IgD-only B cells were able to generate unswitched plasma cells in response to SRBC immunization in both non-competitive and competitive settings (Figure 7—figure supplement 1C–D). Unswitched PC numbers correlate well with MZ B cell numbers in these mice (Figure 4—figure supplement 1B and Figure 4D). Moreover, MZ B cells efficiently generate short-lived unswitched plasma cells even in response to TD-antigens (Phan et al., 2005; Song and Cerny, 2003). We therefore suspect that IgG1 PCs eminate from the Fo B cell compartment, while the unswitched PC response may originate in the MZ B cell compartment. Normal SLPC generation by IgM-deficient MZ B cells in response to immunization would be consistent with previously reported normal T-independent II responses in IgM-deficient mice (Lutz et al., 1998). However, we cannot exclude a contribution of follicular-derived PCs that have failed to class switch to IgG1.

We sought to confirm that the IgG1+PC defect was generalizable to other T-dependent immunogens. The B cell response to NP hapten is stereotyped and makes predominant use of the VH186.2 heavy chain (Loh et al., 1983). We therefore immunized both IgM−/− and IgHα/β mice with NP hapten conjugated to rabbit serum albumin (NP-RSA) in order to control for differences in VDJ locus. Although allotype [a] makes a less robust response to NP than allotype [b], we normalized responses of IgD-only cells to wild type allotype [a] cells and found that GC responses at early time points were intact, but IgG1+ PCs and NP-specific IgG1 titers were significantly reduced 7–8 days after immunization (Figure 7G–I). These data suggest that IgD-only follicular B cells are competent to enter the GC, but they have defects in adopting the SLPC fate (or class-switching) in response to T-dependent immunization.

Discussion

We and others previously hypothesized that a major tolerance strategy employed by autoreactive Fo B cells is selective downregulation of IgM. However, since all Fo B cells express a high and invariant amount of surface IgD, it was unclear whether and how loss of IgM expression could affect B cell responses to antigenic stimulation. It was recently reported that IgM, but not IgD, is uniquely responsive to monomeric antigens due to a short and inflexible linker region coupling the Fab and
Fc portions of IgM (Übelhart et al., 2015). This could account for selective quiescence of mildly autoreactive B cells to monovalent endogenous antigens. However, the identity and structural characteristics of endogenous antigens are not well understood, and include cell-surface antigens on the surface of red cells and B cells (Quách et al., 2011; Reed et al., 2016). Moreover, recent work from Goodnow and colleagues showed that HEL-specific IgD BCR, when expressed on primary mouse splenocytes, can indeed mobilize calcium in vitro and can mediate gene expression changes in vivo in response to monovalent cognate antigen (Sabouri et al., 2016).

How do our observations help move beyond and reconcile the seemingly contradictory published work on antigen sensing by IgM and IgD? In vitro signaling studies of HEL-specific BCRs by the Jumaa and Goodnow labs differ in several important ways; the former work assesses calcium signaling in pre-B cells that lack Slp-65 expression, while the latter studies splenic B cells with a considerably more mature phenotype. In addition, differences in reagents or strength of stimulus may also

**Figure 7.** IgD-only cells have intact germinal center responses but impaired IgG1+ SLPC responses. (A) Splenic (CD19+) B cells from WT, IgM+/−, and IgD−/− mice unimmunized or 5 days after i.p. immunization with 200 μL of 10% SRBCs. (B) Quantification of germinal center (Fashi GL-7hi) cells in (A). (C) Splenocytes from mice in (A). (D) Quantification of CD138+ IgG1+ plasma cells in (C). (E) WT (IgM+/+) and IgM-null (IgD+/+) germinal center B cells as a percentage of live splenocytes in unimmunized and IgM−/− mice 5 days after i.p. immunization with 200 μL of 10% SRBCs. (F) WT (IgG1+/+) and IgM-null (IgG1−/) switched plasma cells (CD138+ IgsG1+) as a percentage of live splenocytes in IgM−/− mice unimmunized or 5 days after i.p. immunization with 200 μL of 10% SRBCs. (G) Fraction of unswitched NP-specific germinal center cells (CD19+ Fashi GL-7hi IgM/IgD+) from the IgH* locus in the spleens of Balb/c-B6 F1 and IgM−/− mice 7–8 days after i.p. immunization with 100 μg NP-RSA. (H) Fraction of IgG1+/CD138+ plasma cells from the IgH* locus in Balb/c-B6 F1 and IgM−/− mice 7–8 days after i.p. immunization with 100 μg NP-RSA. (I) NP-specific IgG1+ and IgG1+ titers at OD = 0.2 were calculated for the mice in (G–H) by ELISA. The IgG1+ to IgG1+ ratio was calculated for each mouse, and all ratios were normalized such that the average IgG1+/IgG1+ ratio in Balb/c-B6 F1 samples = 1.0. For (A–D), statistics from n = 4 unimmunized mice of each genotype and n = 3 WT, n = 6 IgM−/−, and n = 7 IgD−/− immunized mice were pooled. For (A–D), statistics from n = 4 unimmunized mice of each genotype and n = 3 WT, n = 6 IgM−/−, and n = 7 IgD−/− immunized mice were pooled. For (E–F), n = 5 unimmunized and n = 5 immunized mice are shown. For (G–I), n = 5 Balb/c-B6 F1 mice and n = 3 IgM−/− mice are shown. One-way ANOVA with Tukey’s multiple comparisons test (B and D), a paired t test (E–F), and Welch’s t test (G–I) were used to calculate p values, and mean ±SEM is displayed. *p<0.05, **p<0.01, ***p<0.001.

DOI: https://doi.org/10.7554/eLife.35074.035

The following source data and figure supplements are available for figure 7:

**Source data 1.** Numerical data corresponding to germinal center and plasma cell responses in Figure 7B–I, Figure 7—figure supplement 1A–D

DOI: https://doi.org/10.7554/eLife.35074.038

**Figure supplement 1.** Role of BCR allotype and generation of unswitched plasma cells in SRBC-immunized mice.

DOI: https://doi.org/10.7554/eLife.35074.036

**Figure supplement 2.** Role of IgM and IgD in regulating rapid antibody responses.

DOI: https://doi.org/10.7554/eLife.35074.037
contribute to opposing conclusions. Our data suggests that the reduced sensitivity of IgD to bona fide endogenous antigen may lie somewhere between these two extremes; we find that IgD can sense endogenous antigens, just less efficiently than IgM. Consistent with this conclusion, both HEL-specific IgM and IgD BCRs can mediate B cell anergy and drive a common gene expression program in response to chronic high affinity soluble antigen exposure in vivo (Brink et al., 1992; Sabouri et al., 2016).

Here we show that B cells expressing IgD BCR alone inefficiently sense endogenous antigens, and exhibit impaired in vivo cell fate decisions that are dependent upon BCR signal strength. This is epitomized by dramatic skewing of IgD-only B cells away from the B1a and towards the MZ fate in a competitive setting. Importantly, signal transduction mediated by the IgD BCR in response to anti-Igκ stimulation in vitro is intact for all assayed parameters, suggesting that antigen sensing and signal initiation rather than signal transduction downstream of IgD is impaired. We propose that this impaired sensing is conferred by structural properties of IgD, either through direct binding of antigen and signal transduction through the BCR or through differential pairing with co-receptors that directly modulate the BCR signaling pathway.

Characterization of bona fide endogenous antigens that drive Nur77-eGFP expression in the polyclonal repertoire is necessary in order to further dissect the biophysical basis for reduced antigen sensing by IgD in vivo. These antigens may not be exclusively restricted to those that are germline-encoded or generated by host enzymes; rather they may include non-inflammatory antigens taken up through the gastrointestinal tract and recognized by specific BCRs. At least some relevant endogenous antigens may be membrane-bound (Quách et al., 2011; Reed et al., 2016), and recent studies have illustrated the importance of membrane spreading, contraction, and stiffness discrimination in BCR signaling (Fleire et al., 2006; Shaheen et al., 2017). We propose that relevant endogenous antigens are presented in contexts that do not efficiently trigger signaling through the flexible structure of IgD. This might explain the discrepancy between weak responsiveness of IgD to endogenous antigens in vivo and strong signaling in response to crosslinking antibodies in vitro.

An alternative mechanism is that differential clustering of co-receptors with IgD and IgM might influence how BCR signals are integrated in vivo. It has long been proposed that there are not only quantitative, but also qualitative differences between IgM and IgD signaling. Early studies of IgM and IgD signaling in cell lines suggested that kinetics but not quality of signaling triggered by each isotype differed (Kim and Reth, 1995). However, we have been unable to identify a difference in kinetics of BCR signaling in primary IgM- or IgD-deficient B cells in vitro. More recently, studies using TIRF, dSTORM, and PLA (proximity ligation assay) showed that IgD is more densely clustered on the cell surface than IgM, and these distinct IgM- and IgD-containing ‘islands’ are differentially associated with co-receptors such as CD19 in resting and activated B cells (Kläsener et al., 2014; Maity et al., 2015; Mattila et al., 2013). Since function of the ITIM-containing inhibitory co-receptor CD22 depends on its ability to efficiently access the BCR, differences in cluster density of IgM and IgD might render them differentially sensitive to such inhibitory tone (Gasparrini et al., 2016). It is possible that differential association with such co-receptors contributes to differences in the function of the IgM and IgD BCRs in vivo by modulating BCR signal strength, or by selectively perturbing specific downstream signaling events.

In addition to B cell co-receptors that have long been known to directly modulate canonical BCR signaling, a growing list of immunoreceptors expressed on B cells have more recently been shown to require expression of the BCR for optimal function; Becker et al. have shown that expression of the IgD BCR is critical for CXCR4-dependent signaling (Becker et al., 2017). This may influence the biology of B cells expressing only IgM; indeed, CXCR4-deficient B cells exhibit reduced plasma cell migration from spleen to bone marrow (but intact splenic SLPC responses) (Nie et al., 2004). Importantly, defective CXCR4 signaling in IgM-only B cells could not account for reduced Nur77-eGFP expression in IgD-only B cells because reporter expression is insensitive to CXCR4 signaling (Figure 1—figure supplement 1C). Nor would it account for skewed cell fate decisions by IgD-only B cells in competition with wild type B cells, both of which retain intact CXCR4 signaling. B cell responses to TLR4 ligands also require expression of the BCR, but importantly, canonical TLR ligands do not exhibit selective dependence on either the IgM or the IgD isotypes (Figure 1—figure supplement 3A). Finally, recent work establishes a role for the Fc-receptor for IgM in modulating B cell responses, and could therefore play a role downstream of serum IgM that is absent in IgM−/− mice.
Accumulating evidence suggests that strong BCR signals favor SLPC over GC fate (Chan et al., 2009; Nutt et al., 2015; Paus et al., 2006). This is thought to be transcriptionally mediated at least in part by loss of Ets1 expression and induction of Irf4 in a BCR signal-strength dependent manner (Nutt et al., 2015). Here we show that IgM and IgD are each sufficient to drive GC responses, but IgD is less efficient at promoting SLPC fate in response to endogenous antigens, implying that IgD<sup>hi</sup> IgM<sup>lo</sup> B cells may similarly be shunted away from SLPC responses. This discrepancy is unlikely to be attributable to differences in antigen capture and presentation by the IgM and IgD BCRs, as GC entry is highly T cell-help dependent. Instead, we provide evidence to suggest that reduced antigen-dependent BCR signals are transduced in vivo by IgD. We show that, in the absence of Lyn, Ets1 downregulation and unswitched PC expansion require the IgM BCR. IgM<sup>−/−</sup> Lyn<sup>−/−</sup> mice phenocopy Btk<sup>−/−</sup> Lyn<sup>−/−</sup> mice; both strains are protected from Ets1-downregulation, PC expansion, and anti-dsDNA autoantibody production in vivo (Mayeux et al., 2015; Whyburn et al., 2003). This suggests that robust Btk-dependent Ets-1 downregulation in response to endogenous antigens relies upon efficient antigen sensing by the IgM BCR and is important to drive unswitched PC expansion in the absence of Lyn. It will be important to explore whether a similar mechanism accounts for impaired IgG1<sup>+</sup> SLPC responses by Lyn-sufficient B cells with low or absent IgM expression.

We propose that the purpose (and consequence) of IgM downregulation on autoreactive B cells is to limit their direct differentiation into SLPCs in response to chronic endogenous antigen stimulation, and prevent secretion of auto-antibodies in the context of an acute humoral immune response (Figure 7—figure supplement 2A). However, IgD is sufficient to drive germinal center differentiation without the contribution of IgM. This has been well-demonstrated both in the present study as well as prior work (Lutz et al., 1998). Indeed, not only are autoreactive IgD<sup>hi</sup> IgM<sup>lo</sup> B cells competent to enter the germinal center, they appear to do so with greater efficiency, perhaps due in part to improved survival (Sabouri et al., 2016; Sabouri et al., 2014). It is worth emphasizing that selection pressures and tolerance mechanisms operating within the germinal center must independently ensure that somatic hypermutation both abolishes germ-line-encoded autoreactivity and prevents de novo acquisition of autoreactivity. Goodnow and colleagues recently showed that autoreactive BCRs can indeed be ‘redeemed’ by somatic hypermutation, providing proof-of-principle that entry of autoreactive B cells into the GC does not necessarily pose a risk to the organism (Sabouri et al., 2014).

Why, though, are autoreactive B cells preserved in the periphery and not deleted? Why is IgD necessary at all? One suggestion is that such BCRs are retained in the pre-immune B cell compartment to fill holes in the repertoire, and that IgD is essential for their survival; indeed, it has been shown that loss of IgD expression, with or without compensatory upregulation of IgM, leads to loss of mature naive B cells in competition (Roels and Rajewsky, 1993; Sabouri et al., 2016). We similarly find that IgD-only B cells have a profound competitive advantage in the follicular B cell compartment relative to IgM-only (but not WT) B cells, implying an obligate survival function for the IgD isotype BCR. This is consistent with a well-appreciated pro-survival function of the BCR as demonstrated by Rajewsky and colleagues (Kraus et al., 2004; Lam et al., 1997). Since IgD expression is needed to keep IgM<sup>lo</sup> B cells alive, this may explain why IgD expression facilitates a broad dynamic range of IgM expression across the B cell repertoire (Figure 1B,C), allowing B cells to fine-tune the intensity of their SLPC responses according to their autoreactivity. IgD expression on IgM<sup>lo</sup> cells could serve to mediate antigen capture and participation in T-dependent immune responses, while simultaneously limiting SLPC responses as we show here.

We demonstrate here for the first time that IgD BCRs sense endogenous antigen more weakly than IgM BCRs in vivo, are inefficient at driving SLPC responses to endogenous antigens, and thereby may function to divert autoreactive follicular B cells from direct PC differentiation. We propose that this property of the IgD BCR limits generation of auto-reactive antibodies in the context of immediate humoral immune responses. Taken together with recent work from the Jumaa and Goodnow groups, we propose a unified model of how IgM downregulation in the face of high IgD expression regulates the fate of naive autoreactive B cells in vivo while retaining their contribution to the mature BCR repertoire.
# Materials and methods

## Key resources table

| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
|-----------------------------------|-------------|--------------------|-------------|------------------------|
| Strain, strain background (Mus musculus) | C56BL/6 | The Jackson Laboratory, Taconic | JAX:000664, TAC:BCNTac | |
| Strain, strain background (M. musculus) | Balb/C | The Jackson Laboratory | JAX:000651 | |
| Strain, strain background (M. musculus) | Nur77-eGFP | MMRRC UC Davis | MMRRC:012015-UCD | Characterized in PMID:22902503 |
| Strain, strain background (M. musculus) | IgHEL | PMID:3261841 | | MD-4 |
| Strain, strain background (M. musculus) | sHEL | PMID:3261841 | | ML-5 |
| Strain, strain background (M. musculus) | IgM/- | PMID:9655395 | | |
| Strain, strain background (M. musculus) | IgD/- | PMID:8446604 | | |
| Strain, strain background (M. musculus) | CD40L/- | PMID:7964465 | | |
| Strain, strain background (M. musculus) | Unc93b 3d/3d | PMID:16415873 | | |
| Strain, strain background (M. musculus) | TLR7/- | PMID:15034168 | | |
| Strain, strain background (M. musculus) | BaffTg | MMRRC UC Davis | RRID:MMRRC_036508-UCD | Described in PMID:15972664 |
| Strain, strain background (M. musculus) | B6.IgHa | The Jackson Laboratory | JAX:001317 | B6.Cg-Gpi1a Thy1a Igha/J |
| Strain, strain background (M. musculus) | Lyn-/- | PMID:9252121 | | |
| Strain, strain background (M. musculus) | MB1-Cre | PMID:16940357 | | |
| Strain, strain background (M. musculus) | MyD88 fl/fl | PMCID:PMC2847796 | | |
| Strain, strain background (M. musculus) | Nr4a1/- | PMID:7624775 | JAX:006187 | |
| Biological sample (Ovis aires) | Sheep Red Blood Cells | Rockland | R406-0050 | |
| Antibody | Anti-B220-A647 (rat monoclonal) | BD Pharmingen | 557683 (1.200) | |
| Antibody | Anti-B220-APC-e780 (rat monoclonal) | eBioscience | 47-0452-82 (1.400) | |
| Antibody | Anti-B220-FITC (rat monoclonal) | Tonbo | 35-0452 U100 (1.200) | |
| Antibody | Anti-B220-Pacific Blue (rat monoclonal) | Tonbo | 75-0452 U100 (1.200) | |
| Antibody | Anti-B220-PE (rat monoclonal) | BD Pharmingen | 553090 (1.200) | |
| Antibody | Anti-B220-PE-Cy7 (rat monoclonal) | BD Pharmingen | 553090 (1.200) | |
| Antibody | Anti-B220-PerCP-Cy5.5 (rat monoclonal) | Tonbo | 65-0452 U100 (1.200) | |
| Antibody | Anti-CD5-APC (rat monoclonal) | Tonbo | 20-0051 U100 (1.100) | |

Continued on next page
| Reagent type (species) or resource | Designation                     | Source or reference | Identifiers      | Additional information |
|-----------------------------------|---------------------------------|---------------------|------------------|------------------------|
| Antibody                          | Anti-CD19-PE-Cy7 (rat monoclonal)| Biolegend           | 115520           | (1:150)                |
| Antibody                          | Anti-CD19-PerCP-Cy5.5 (rat monoclonal) | BD Pharmingen   | 551001           | (1:150)                |
| Antibody                          | Anti-CD21-A647 (rat monoclonal)   | Biolegend           | 123424           | (1:100)                |
| Antibody                          | Anti-CD21-Pacific Blue (rat monoclonal) | Biolegend         | 123414           | (1:100)                |
| Antibody                          | Anti-CD23-A647 (rat monoclonal)   | Biolegend           | 101612           | (1:200)                |
| Antibody                          | Anti-CD23-FITC (rat monoclonal)   | BD Pharmingen      | 553138           | (1:200)                |
| Antibody                          | Anti-CD23-Pacific Blue (rat monoclonal) | Biolegend         | 101616           | (1:100)                |
| Antibody                          | Anti-CD23-PE (rat monoclonal)     | BD Pharmingen      | 553139           | (1:200)                |
| Antibody                          | Anti-CD23-PE-Cy7 (rat monoclonal) | eBioscience        | 25-0232-82       | (1:200)                |
| Antibody                          | Anti-CD69-APC (hamster monoclonal) | Biolegend           | 104514           | (1:100)                |
| Antibody                          | Anti-CD69-PE-Cy7 (hamster monoclonal) | Torbo              | 60-0691 U100     | (1:100)                |
| Antibody                          | Anti-CD86-Pacific Blue (rat monoclonal) | Biolegend         | 105022           | (1:100)                |
| Antibody                          | Anti-CD93 (AA4.1)-PE-Cy7 (rat monoclonal) | Biolegend       | 136506           | (1:100)                |
| Antibody                          | Anti-CD138-PE (rat monoclonal)     | Biolegend           | 142504           | (1:100)                |
| Antibody                          | Anti-CD138-PE-Cy7 (rat monoclonal) | Biolegend           | 142513           | (1:100)                |
| Antibody                          | Anti-CXCR4-Biotin (rat monoclonal) | Biolegend           | 551968           | (1:100)                |
| Antibody                          | Anti-ETS1 (rabbit monoclonal)      | Epitomics, abcam    | EPI:3123–1; AB:109212 | (1:10,000); concentrated lot from L.A. Garrett-Sinha |
| Antibody                          | Anti-Fas-PE-Cy7 (hamster monoclonal) | BD Pharmingen      | 557653           | (1:200)                |
| Antibody                          | Anti-GAPDH (mouse monoclonal)      | EMD Millipore      | AB2302           | (1:2000)               |
| Antibody                          | GL-7-A647 (rat monoclonal)         | BD Biosciences      | 561529           | (1:400)                |
| Antibody                          | Anti-IgA-Biotin (rat monoclonal)    | Biolegend           | 407003           | (1:400)                |
| Antibody                          | Anti-IgD (goat polyclonal serum)    | MD Biosciences      | 2057001          | (1:50-1:400)           |
| Antibody                          | Anti-IgD(a,b)-Biotin (mouse monoclonal) | BD Pharmingen | 553506           | (1:300)                |
| Antibody                          | Anti-IgD-APC-e780 (rat monoclonal)  | eBioscience         | 47-5993-80       | (1:500)                |
| Antibody                          | Anti-IgD-HRP (rat monoclonal)       | American Research Products | 09-1008-4    | (1:2000)               |
| Antibody                          | Anti-IgD-Pacific Blue (rat monoclonal) | Biolegend        | 405712           | (1:300)                |

*Continued on next page*
| Reagent type | Designation | Source or reference | Identifiers | Additional information |
|--------------|-------------|---------------------|-------------|------------------------|
| Antibody | Anti-IgD-PE (rat monoclonal) | eBioscience | 12-5993-82 | (1:800) |
| Antibody | Anti-IgG1[a]-Biotin (mouse monoclonal) | BD Pharmingen | 553500 | (1:300) |
| Antibody | Anti-IgG1[b]-Biotin (mouse monoclonal) | BD Pharmingen | 553533 | (1:300) |
| Antibody | Anti-IgG2a[a]-Biotin (mouse monoclonal) | BD Biosciences | 553502 | (1:1000) |
| Antibody | Anti-IgG2a[b]-Biotin (mouse monoclonal) | BD Biosciences | 553504 | (1:1000) |
| Antibody | Anti-IgG2c-Biotin (goat polyclonal) | SouthernBiotech | 1079-08 | (1:1000) |
| Antibody | Anti-IgG (goat polyclonal) | SouthernBiotech | 1050-01 | 1–20 μg/mL |
| Antibody | Anti-IgG-F(ab')2 (goat polyclonal) | SouthernBiotech | 1052-01 | 1–20 μg/mL |
| Antibody | Anti-IgG-FITC (goat polyclonal) | SouthernBiotech | 1050-02 | (1:300) |
| Antibody | Anti-IgG-FITC (rat monoclonal) | BD Pharmingen | 550003 | (1:300) |
| Antibody | Anti-IgG-PerCP-Cy5.5 (rat monoclonal) | BD Pharmingen | 560668 | (1:300) |
| Antibody | Anti-IgG-FITC (rat monoclonal) | BD Pharmingen | 553434 | (1:300) |
| Antibody | Anti-IgG-PE (rat monoclonal) | Biolegend | 407307 | (1:300) |
| Antibody | Anti-IgG-F(ab')2 (goat polyclonal) | Jackson ImmunoResearch | 115-006-020 | 1–20 μg/mL |
| Antibody | Anti-IgM-HRP (goat polyclonal) | SouthernBiotech | 1020-05 | (1:2000); secondary for ELISA |
| Antibody | Anti-IgM[a]-Biotin (mouse monoclonal) | Biolegend | 408603 | (1:100) |
| Antibody | Anti-IgM[a]-FITC (mouse monoclonal) | Biolegend | 408606 | (1:100); (1:400) for plasma cell |
| Antibody | Anti-IgM[b]-PE (mouse monoclonal) | BD Pharmingen | 553517 | (1:100); (1:400) for plasma cell |
| Antibody | Anti-IgM[b]-Biotin (mouse monoclonal) | Biolegend | 406204 | (1:100) |
| Antibody | Anti-IgM[b]-PE (mouse monoclonal) | Biolegend | 406208 | (1:100); (1:400) for plasma cell |
| Antibody | Anti-IgM-APC (mouse monoclonal) | eBioscience | 17-5790-82 | (1:100) |
| Antibody | Anti-MHC-2-APC (rat monoclonal) | Tonbo | 20-5321 U100 | (1:1000) |
| Antibody | Anti-Mouse-IgG(H + L)-HRP (goat polyclonal) | SouthernBiotech | 1031-05 | (1:5000); secondary for western blots |
| Antibody | Anti-Nur77-PE (mouse monoclonal) | eBioscience | 12-5965-80 | (1:100) |
| Antibody | Anti-pERK (rabbit monoclonal) | Cell Signaling Technology | 43775 | (1:80) |
| Antibody | Anti-pS6 (rabbit monoclonal) | Cell Signaling Technology | 48565 | (1:100) |
| Antibody | Anti-Rabbit-IgG-APC (donkey polyclonal) | Jackson ImmunoResearch | 711-136-152 | (1:100); secondary for pERK/pS6 |

Continued on next page
| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
|-----------------------------------|-------------|---------------------|------------|------------------------|
| Antibody                         | Anti-Rabbit-IgG(H + L)-HRP (goat polyclonal) | SouthernBiotech | 4050-05 | (1:5000); secondary for western blots |
| Sequence-based reagent           | Nr4a1 forward primer | Elim Biopharm | gcctagcactgcaaatg |
| Sequence-based reagent           | Nr4a1 reverse primer | Elim Biopharm | ggaaccagagagcaagctcat |
| Sequence-based reagent           | GAPDH forward primer | Elim Biopharm | aggtcgggtgagacgaggttg |
| Sequence-based reagent           | GAPDH reverse primer | Elim Biopharm | tgtagacagctgtgaggtca |
| Peptide, recombinant protein     | NP-RSA      | Biosearch           | N-5054-100 | Conj. ratio: 10 |
| Peptide, recombinant protein     | NP-BSA      | Biosearch           | N-5050H-100 | Conj. ratio: 23 |
| Peptide, recombinant protein     | Streptavidin-HRP | SouthernBiotech    | 7100-05 | (1:5000) |
| Peptide, recombinant protein     | Streptavidin-APC | Tonbo              | 20-4317 U500 | (1:100-1:400) |
| Peptide, recombinant protein     | Streptavidin-Pacific Blue | Life Technologies | S11222 | (1:200) |
| Peptide, recombinant protein     | Streptavidin-PerCP-Cy5.5 | BD Pharmingen | 551419 | (1:400) |
| Peptide, recombinant protein     | Streptavidin-FITC | Biolegend           | 405202 | (1:100-1:200) |
| Peptide, recombinant protein     | CXCL12      | Peprotech           | 300-28A   |
| Peptide, recombinant protein     | NP-PE       | Biosearch           | N-5070–1  | (1:400) |
| Chemical compound, drug          | Poly-L-Lysine | Sigma               | P2636-100MG | 100 µg/mL in 0.1 M Tris-HCl pH7.3 |
| Chemical compound, drug          | Poly dA-dT   | Sigma               | P0883-50UN | 0.2 U/mL in 0.1 M Tris-HCl pH7.3 |
| Chemical compound, drug          | LPS         | Sigma               | L8274     |
| Chemical compound, drug          | CpG         | InvivoGen           | tlr-1826b |
| Commercial assay, kit            | Indo-1, AM  | Life Technologies   | I-1223    | (1:1000) |
| Commercial assay, kit            | Live/Dead Fixable Near-IR Dead Cell Stain Kit | Invitrogen | L10119 | (1:1000) |
| Commercial assay, kit            | ECL Luminal, Oxidizer Reagents | Perkin Elmer | ORT2751; ORT2651 |
| Commercial assay, kit            | 3,3’-5,5’-Tetramethylbenzidine, Slow Kinetic Form | Sigma | T4319-100ML | ELISA substrate |
| Software, algorithm              | FlowJo      | FlowJo LLC          | Version 9.9.4 |
| Software, algorithm              | Prism       | GraphPad            | Version 7.0b |
| Software, algorithm              | Canopy      | Enthought           | Version 1.4.1.1975 |
| Software, algorithm              | Binning program in Figure 1F | Other | Source code provided in this publication |
| Other                            | BD Microtainer Capillary Blood Collector | Fisher | 365967 |
| Other                            | PtC-Rhodamine (DOPC/CHOL Liposomes) | FormuMax | F60103F-R | (1:1000); used in PtC-specific B1a staining |
| Other                            | NuPAGE 4–12% Bis-Tris Protein Gels | Invitrogen | NP033SBOX |
| Other                            | Immobilon-P PVDF Membrane | EMD Millipore | IPVH00010 |
| Other                            | Assay Plate, 96 Well, No Lid, Vinyl | Costar | 2595 | Used for ELISA |
Mice
Nur77-eGFP mice and Lyn−/− mice have been previously described (Chan et al., 1997; Zikherman et al., 2012). BAFF Tg mice were originally generated in the Nemazee lab, and express BAFF under the control of the myeloid promoter human CD68 (Gavin et al., 2005) (source: MMRRC UC Davis). IgD−/− and IgM−/− mice were previously described, and the former were generously shared by Dr. Hassan Jumaa (Lutz et al., 1998; Nitschke et al., 1993). TLR7−/−, CD40L−/−, Unc93b1Δ/Δ, N4a1−/−, and MB1-Cre MyD88f/f mice were previously described (Hobeika et al., 2006; Hou et al., 2008; Lee et al., 1995; Lund et al., 2004; Renshaw et al., 1994; Tabela et al., 2006). All strains were backcrossed to the C57BL/6 genetic background for at least six generations. Mice were used at 5–12 weeks of age for all functional and biochemical experiments unless otherwise noted. Germ-free (GF) and specific pathogen free (SPF) C57BL/6 mice used for direct comparison were purchased from Taconic and Jackson Laboratory and kept in microisolators under GF or SPF (ISOcage P - Bioexclusion System, Tecniplast) conditions. All GF mice were housed in closed caging systems and provided with standard irradiated chow diet, acidified water and housed under a 12 hr light cycle; 7-week-old males mice were used. GF and control mice were generously provided by Drs. Sergio Baranzini and Anne-Katrin Proebstel at UCSF. All other mice used in our studies were housed in a specific pathogen free facility at UCSF according to the University Animal Care Committee and National Institutes of Health (NIH) guidelines.

Antibodies and reagents
Fluorescently-conjugated or biotin-conjugated antibodies to B220, CD5, CD19, CD21, CD23, CD69, CD86, CD93 (AA4.1), CD95 (Fas), CD138, CXCIR4, IgA, IgM, IgM[a], IgM[b], IgD, IgD[a], IgG1[a], IgG1[b], Igx, Igλ, GL-7, MHC Class II, and fluorescently-conjugated streptavidin were from Biolegend, eBiosciences, BD Biosciences, Tonbo, or Life Technologies. NP-PE was from Biosearch Technologies. 100 nm Rhodamine PtC liposomes were from FormuMax. Antibodies for intra-cellular staining, pErk Ab (clone 194g2) and pS6 Ab (2F9), were from Cell Signaling Technologies, and Nur77 Ab (clone 12.14) conjugated to PE was from eBioscience. Goat anti-mouse IgM F(ab’)2 was from Jackson Immunoresearch. Goat anti-mouse Igξ and goat F(ab’)2 anti-mouse Igκ were from Southern Biotech. Anti-IgD was from MD Biosciences. CXCIR4 ligand (CXCL12/hSDF-1α) was from Peprotech. LPS (Cat. L8274) was from Sigma. CpG DNA (ODN 1826 Biotin; Cat. tlr-1826b) and Pam3CSK4 (Cat. tlr-pms) were from InvivoGen.

Flow cytometry and data analysis
Cells were stained with indicated antibodies and analyzed on a Fortessa (Becton Dickson) as previously described (Hermiston et al., 2005). Data analysis was performed using FlowJo (v9.7.6) software (Treestar Incorporated, Ashland, OR). Statistical analysis and graphs were generated using Prism v6 (GraphPad Software, Inc). Figures were prepared using Illustrator CS6 v16.0.0. Median Igκ levels (Figure 1F) were calculated for 200 equally sized ‘bins’ spanning the Nur77-eGFP spectrum using Canopy v1.4.1 (Enthought); source code is provided, and parameters can be modified to condense any 2D FACS plot for comparisons of multiple samples.

Statistics and replicates
We define biological replicates as independent analyses of cells isolated from different mice of the same genotype, and we define technical replicates as analyses of cells isolated from the same mouse and used in the same experiment. When technical replicates were used, we averaged them to calculate a value for the biological replicate. All reported values and statistics correspond to biological replicates only, and all ‘n’ values reported reflect the number of biological replicates. Wherever MFIs are directly compared, we collected all samples in a single experiment to avoid potential error that could arise from fluctuations in our flow cytometers. In some instances, MFI ratios were compiled from different experiments for statistical purposes, but qualitative findings were consistent experiment to experiment. As our panels reproducibly generated flow plots with well-defined populations, population sizes were calculated from data compiled from different experiments. When comparing two groups, we employed Welch’s t test, which is more stringent than Student’s t test and does not assume that the groups have the same standard deviation. We used paired difference t tests when studying parameters in allotype-heterozygous mice that are sensitive to cell-extrinsic factors (e.g.
dose of immunogen or severity of autoimmune disease). When comparing three genotypes (e.g. receptor levels on WT vs. \( \text{IgM}^{-/-} \) vs. \( \text{IgD}^{-/-} \) B cells), we used one-way ANOVA and Tukey’s multiple comparison test to calculate p values.

**Intracellular Nur77, pErk and pS6 staining**

Ex vivo or following stimulation, cells were fixed in 2% paraformaldehyde, permeabilized with 100% methanol, and stained with anti-Nur77, anti-pErk, or anti-pS6 followed by lineage markers and secondary antibodies if needed.

**Intracellular plasma cell staining**

Cells were fixed in 2% paraformaldehyde and permeabilized in BD Perm/Wash. Stains for antibody isotypes and allotypes were prepared in BD Perm/Wash.

**Intracellular calcium flux**

Cells were loaded with 5 \( \mu \text{g/mL} \) Indo-1 AM (Life Technologies) and stained with lineage markers. Cells were rested at 37 C for 2 min, and Indo-1 fluorescence was measured immediately prior to stimulation to calculate basal calcium, and for at least two minutes following addition of stimulus.

**In vitro B cell stimulation**

Splenocytes or lymphocytes were harvested into single cell suspension, subjected to red cell lysis using ACK buffer, and plated at a concentration of \( 7.5 \times 10^5 \) cells/200 \( \mu \text{L} \) in round bottom 96 well plates in complete RPMI media with stimuli for 18 hours prior to analysis. In vitro cultured cells were stained using fixable near IR live/dead stain (Life technologies) per manufacturer’s instructions.

**ELISA**

Serum antibody titers for total IgM, total IgD, anti-dsDNA IgG2a, and NP-specific IgG1 were measured by ELISA. For total IgM and total IgD, 96-well plates (Costar) were coated with 1 \( \mu \text{g/mL} \) anti-IgM \( \text{F(ab')}_2 \) (Jackson) or 1 \( \mu \text{g/mL} \) anti-IgD (BD 553438), respectively. Sera were diluted serially, and total IgM and total IgD were detected with anti-IgM-biotin (eBioscience) and SA-HRP (Southern Biotech) or anti-IgD-HRP (American Research Products). dsDNA plates were generated by serially coating plates with 100 \( \mu \text{g/mL} \) poly-L-lysine (SigmaAldrich) and 0.2 U/mL poly dA-dT (SigmaAldrich) in 0.1 M Tris-HCL pH 7.6. Sera were diluted serially on dsDNA plates, and autoantibodies were detected with IgG2[a]-biotin, IgG2a[b]-biotin, and SA-HRP. NP plates were generated by coating 96-well plates with 1 \( \mu \text{g/mL} \) NP-BSA (Biosearch, conjugation ratio 23) in PBS. Sera from NP-RSA immunized and unimmunized mice were diluted serially, and NP-specific IgG1 was detected with IgG1[a]-biotin, IgG1[b]-biotin, and SA-HRP. All ELISA plates were developed with TMB (Sigma) and stopped with 2N sulfuric acid. Absorbance was measured at 450 nm. For total IgM, total IgD, and dsDNA IgG2a, OD values or OD ratios were calculated and displayed. For NP-specific IgG1, titers were calculated at OD = 0.2 and normalized such that the average IgG1[a]/IgG1[b] ratio in immunized Balb/c-C57BL/6 F1 mice equals 1.0.

**B cell purification and western blots**

Splenic B cells were purified by negative selection with a MACS kit according to manufacturer’s protocol (Miltenyi Biotech, cat# 130-090-862). Purified B cells were lysed in 2N 4X SDS and boiled at 95 C for 5 min. 500,000 cells per lane were loaded onto NuPAGE 4–12% Bis-Tris gels (Invitrogen NP0335), run for 50 min at 200V, and transferred onto PVDF membranes using an XCell II Blot Module (Invitrogen). Membranes were blocked with 3% BSA. Proteins were detected with rabbit monoclonal anti-Ets1 (Epitomics, custom lot provided by Lee Ann Garrett-Sinha), mouse anti-mouse GAPDH (Santa Cruz Biotechnology 32332), and HRP-conjugated secondary antibodies goat anti-rabbit IgG (H + L) and goat anti-mouse IgG (H + L) (SouthernBiotech). Membranes were developed with Western Lightning Plus ECL (Perkin Elmer 0RT2651 and 0RT2751) and imaged using a ChemiDoc Touch Imaging System (Bio-Rad). Quantifications were performed using Image Lab v. 5.2.14 (Bio-Rad).
Immunizations
Mice were immunized i.p. with 200 μL of 10% sheep red blood cells (Rockland R406-0050) diluted in PBS. Mice were sacrificed 5 days after immunization, and serum and spleens were harvested. Mice were immunized i.p. with 100 μg of NP-conjugated rabbit serum album (NP-RSA, Biosearch N-5054–10, conjugation ratio 10) prepared in PBS with Alhydrogel 1% adjuvant (Accurate Chemical and Scientific Corp. 21645-51-2). NP-RSA immunized mice were sacrificed 7–8 days following immunization, and serum and spleens were harvested. To ensure that our calculated values accurately reflect the magnitude and variability of immune responses induced by immunization, we analyzed all mice that had larger plasma cell and germinal center compartments than unimmunized mice. One IgM+/– mouse immunized with SRBCs (Figure 7E–F) was excluded because it did not display an expanded plasma cell compartment; no other mice were excluded from analysis.

Quantitative PCR
Splenocytes were lysed in TRIzol (Invitrogen) and stored at −80 °C. cDNA was prepared using a SuperScriptIII kit (Invitrogen). Quantitative PCR reactions were run on a QuantStudio 12K Flex thermal cycler (Applied Biosystems) with FastStart Universal SYBR Green Master Mix (Roche). Nr4a1 (forward: gcctagcactgccaaattg; reverse: ggaaccagagagcaagtcat) and GAPDH (forward: aggtcggtgtgaacggatttg; reverse: ttagacactgtagttgaggtca) primers were used at 250 nM each.

Acknowledgements
We thank Anthony DeFranco, Arthur Weiss, and Jason Cyster for valuable feedback and suggestions for this manuscript, and Al Roque for help with mouse husbandry. We thank Renuka Nayak, Anne-Katrin Proebstel, and Eric Wigton for sharing valuable mouse reagents. Funding for this project was provided by the Rheumatology Research Foundation (JZ), NIAMS K08 AR059723 and R01 A127648 (JZ), and NSF Graduate Research Fellowship 1650113 (MN).

Additional information

Funding

| Funder                                | Grant reference number | Author            |
|---------------------------------------|------------------------|-------------------|
| National Science Foundation           | 1650113                | Mark Noviski      |
| National Institute of Arthritis and Musculoskeletal and Skin Diseases | R01 A127648           | Julie Zikherman   |
| Rheumatology Research Foundation      |                        | Julie Zikherman   |
| National Institute of Arthritis and Musculoskeletal and Skin Diseases | NIAMS K08 AR059723    | Julie Zikherman   |

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Author contributions
Mark Noviski, Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Writing—original draft, Writing—review and editing; James L Mueller, Formal analysis, Investigation; Anne Satterthwaite, Lee Ann Garrett-Sinha, Frank Brombacher, Resources, Writing—review and editing; Julie Zikherman, Conceptualization, Data curation, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Writing—original draft, Project administration, Writing—review and editing
Ethics
Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols of the University of California, San Francisco. The protocol was approved by the IACUC committee of the University of California, San Francisco (Protocol number: AN171020-01).

References
Baumgarth N. 2011. The double life of a B-1 cell: self-reactivity selects for protective effector functions. Nature Reviews Immunology 11:34–46. DOI: https://doi.org/10.1038/nri2901, PMID: 21151033
Becker M, Hobeika E, Jumaa H, Reth M, Maity PC. 2017. CXCR4 signaling and function require the expression of the IgD-class B-cell antigen receptor. PNAS 114:5231–5236. DOI: https://doi.org/10.1073/pnas.1621512114, PMID: 28461496
Blum JH, Stevens TL, DeFranco AL. 1993. Role of the mu immunoglobulin heavy chain transmembrane and cytoplasmic domains in B cell antigen receptor expression and signal transduction. The Journal of Biological Chemistry 268:27236–27245. PMID: 8262964
Boes M, Esau C, Fischer MB, Schmidt T, Carroll M, Chen J. 1998. Enhanced B-1 cell development, but impaired IgG antibody responses in mice deficient in secreted IgM. Journal of Immunology 160:4776–4787. DOI: https://doi.org/10.4049/jimmunol.0901690, PMID: 19666991
Brink R, Goodnow CC, Crosbie J, Adams E, Eris J, Mason DY, Hartley SB, Basten A. 1992. Immunoglobulin M and D antigen receptors are both capable of mediating B lymphocyte activation, deletion, or anergy after interaction with specific antigen. Journal of Experimental Medicine 176:991–1005. DOI: https://doi.org/10.1084/jem.176.4.991, PMID: 1402669
Cambier JC, Gauld SB, Merrell KT, Vilen BJ. 2007. B-cell anergy: from transgenic models to naturally occurring anergic B cells? Nature Reviews Immunology 7:633–643. DOI: https://doi.org/10.1038/nri2133, PMID: 17641666
Cariappa A, Pillai S. 2002. Antigen-dependent B-cell development. Current Opinion in Immunology 14:241–249. DOI: https://doi.org/10.1016/S1074-7613(00)80511-7, PMID: 11869899
Casola S, Otipoby KL, Alimzhanov M, Humme S, Uyttersprot N, Kutok JL, Carroll MC, Rajewsky K. 2004. B cell receptor signal strength determines B cell fate. Nature Immunology 5:317–327. DOI: https://doi.org/10.1038/ni1036, PMID: 14758357
Chan TD, Gatto D, Wood K, Camidge T, Basten A, Brink R. 2009. Antigen affinity controls rapid T-dependent antibody production by driving the expansion rather than the differentiation or extrafollicular migration of early plasmablasts. The Journal of Immunology 183:3139–3149. DOI: https://doi.org/10.4049/jimmunol.0901690, PMID: 19666991
Chan VW, Meng F, Soriano P, DeFranco AL, Lowell CA. 1997. Characterization of the B lymphocyte populations in Lyn-deficient mice and the role of Lyn in signal initiation and down-regulation. Immunity 7:69–81. DOI: https://doi.org/10.1016/S1074-7613(00)80511-7, PMID: 9252121
Chen K, Cerutti A. 2010. New insights into the enigma of immunoglobulin D. Immunological Reviews 237:160–179. DOI: https://doi.org/10.1111/j.1600-065X.2010.00929.x, PMID: 20727035
Duty JA, Szodoray P, Zheng NY, Koelsch KA, Zhang Q, Swiatkowski M, Mathias M, Garman L, Helms C, Nakken B, Smith K, Farris AD, Wilson PC. 2009. Functional anergy in a subpopulation of naive B cells from healthy humans that express autoreactive immunoglobulin receptors. The Journal of Experimental Medicine 206:139–151. DOI: https://doi.org/10.1084/jem.20080611, PMID: 19103878
Enders A, Short A, Miosge LA, Bergmann H, Sontani Y, Bertram EM, Whittle B, Balakishnan B, Yoshida K, Spillerna G, Field MA, Andrews TD, Hagiwara H, Goodnow CC. 2014. Zinc-finger protein ZFP318 is essential for expression of IgD, the alternatively spliced Ig product made by mature B lymphocytes. PNAS 111:4513–4518. DOI: https://doi.org/10.1073/pnas.1402739111, PMID: 24616512

Fleire SJ, Goldman JP, Carrasco YR, Weber M, Bray D, Batista FD. 2006. B cell ligand discrimination through a spreading and contraction response. Science 312:738–741. DOI: https://doi.org/10.1126/science.1123940, PMID: 16675699

Gasparini F, Feest C, Bruckbauer A, Mattila PK, Müller J, Nitschke L, Bray D, Batista FD. 2016. Nanoscale organization and dynamics of the siglec CD22 cooperate with the cytoskeleton in restraining BCR signalling. The EMBO Journal 35:258–280. DOI: https://doi.org/10.15252/embj.201593027, PMID: 26671981

Gavin AL, Duong B, Skog P, Att-Azzouzene D, Greaves DR, Scott ML, Nemaze D. 2005. deltaBAFF, a splice isoform of BAFF, opposes full-length BAFF activity in vivo in transgenic mouse models. The Journal of Immunology 175:319–328. DOI: https://doi.org/10.4049/jimmunol.175.1.319, PMID: 15972664

Goodnow CC, Crosbie J, Adelstein S, Lavoie TB, Smith-Gill SJ, Brink RA, Pritchard-Briscoe H, Wootsponser JS, Loblay RH, Raphael K. 1988. Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. Nature 334:676–682. DOI: https://doi.org/10.1038/334676a0, PMID: 3261841

Goodnow CC, Crosbie J, Jorgensen H, Brink RA, Basten A. 1989. Induction of self-tolerance in mature peripheral B lymphocytes. Nature 342:385–391. DOI: https://doi.org/10.1038/342349a0, PMID: 2586609

Gutierrez T, Halcomb KE, Coughran AJ, Li QZ, Satterthwaite AB. 2010. Separate checkpoints regulate splenic plasma cell accumulation and IgG autoantibody production in Lyn-deficient mice. European Journal of Immunology 40:1897–1905. DOI: https://doi.org/10.1002/eji.200940043, PMID: 20394076

Hermiston ML, Tan AL, Gupta VA, Majeti R, Weiss A. 2005. The juxtamembrane wedge negatively regulates CD45 function in B cells. Immunity 23:635–647. DOI: https://doi.org/10.1016/j.immuni.2005.11.001, PMID: 16356861

Hibbs ML, Tarlinton DM, Armes J, Grail D, Hodgson G, Maglitto R, Stacker SA, Dunn AR. 1995. Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell 83:301–311. DOI: https://doi.org/10.1016/0092-8674(95)90171-X, PMID: 7585947

Hobeika E, Thiemann S, Storch B, Jumaa H, Nielsen PJ, Pelanda R, Reth M. 2006. Testing gene function early in the B cell lineage in mb1-cre mice. PNAS 103:13789–13794. DOI: https://doi.org/10.1073/pnas.0605944103, PMID: 16940357

Hombach J, Tsutbata T, Leclercq L, Stappert H, Reth M. 1990. Molecular components of the B-cell antigen receptor complex of the IgM class. Nature 343:760–762. DOI: https://doi.org/10.1038/343760a0, PMID: 2304550

Hou B, Reizis B, DeFranco AL. 2008. Toll-like receptors activate innate and adaptive immunity by using dendritic cell-intrinsic and -extrinsic mechanisms. Immunity 29:272–282. DOI: https://doi.org/10.1016/j.immuni.2008.05.016, PMID: 18656388

Hua Z, Gross AJ, Lamagna C, Ramos-Hernández N, Scapini P, Ji M, Shao H, Lowell CA, Hou B, DeFranco AL. 2014. Requirement for MyD88 signaling in B cells and dendritic cells for germinal center anti-nuclear antibody production in Lyn-deficient mice. The Journal of Immunology 192:875–885. DOI: https://doi.org/10.4049/jimmunol.1300683, PMID: 24379120

Infantino S, Jones SA, Walker JM, Maxwell MJ, Light A, O’Donnell K, Tsantikos E, Peperzak V, Phesse T, Ernst M, Mackay F, Hibbs ML, Fairfax KA, Tarlinton DM. 2014. The tyrosine kinase Lyn limits the cytokine responsiveness of plasma cells to restrict their accumulation in mice. Science Signaling 7:ra77. DOI: https://doi.org/10.1126/scisignal.2005105, PMID: 25118329

John SA, Clements JL, Russell LM, Garrett-Sinha LA. 2008. Ets-1 regulates plasma cell differentiation by interfering with the transcription factor Blimp-1. Journal of Biological Chemistry 283:951–962. DOI: https://doi.org/10.1074/jbc.M705262200, PMID: 17977828

Kim KM, Reth M. 1995. Signaling difference between class IgM and IgD antigen receptors. Annals of the New York Academy of Sciences 766:81–88. DOI: https://doi.org/10.1111/j.1749-6632.1995.tb26651.x, PMID: 7486702

Kirchenbaum GA, St Clair JB, Detanico T, Aviszus K, Wysocki LJ. 2014. Functionally responsive self-reactive B cells of low affinity express reduced levels of surface IgM. European Journal of Immunology 44:970–982. DOI: https://doi.org/10.1002/eji.201344276, PMID: 24375379

Klässener K, Maity PC, Hobeika E, Yang J, Reth M. 2014. B cell activation involves nanoscale receptor reorganizations and inside-out signaling by Syk. eLife 3:e02069. DOI: https://doi.org/10.7554/eLife.02069, PMID: 24963139

Kraus M, Alimzhanov MB, Rajewsky N, Rajewsky K. 2004. Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell 117:787–800. DOI: https://doi.org/10.1016/j.cell.2004.05.014, PMID: 15186779

Lam KP, Kühn R, Rajewsky K. 1997. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell 90:1073–1083. DOI: https://doi.org/10.1016/S0092-8674(00)80373-6, PMID: 9323135

Lamagna C, Hu Y, DeFranco AL, Lowell CA. 2014. B cell-specific loss of Lyn kinase leads to autoimmunity. The Journal of Immunology 192:919–928. DOI: https://doi.org/10.4049/jimmunol.1301979, PMID: 24376269

Lee SL, Wesselschmidt RL, Linette GP, Kanagawa O, Russell JH, Milbrandt J. 1995. Unimpared thymic and peripheral T cell death in mice lacking the nuclear receptor NGFI-B (Nur77). Science 269:532–535. DOI: https://doi.org/10.1126/science.7624775, PMID: 7624775
Liu Z, Zou Y, Davidson A. 2011. Plasma cells in systemic lupus erythematosus: the long and short of it all. European Journal of Immunology 41:588–591. DOI: https://doi.org/10.1002/eji.201041354, PMID: 21341259

Loh DY, Bothwell AL, White-Scharf ME, Imanishi-Kari T, Baltimore D. 1983. Molecular basis of a mouse strain-specific anti-hapten response. Cell 33:85–93. DOI: https://doi.org/10.1016/0092-8674(83)90337-9, PMID: 6432337

Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, Gale NW, Iwasaki A, Flavell RA. 2004. Recognition of single-stranded RNA viruses by Toll-like receptor 7. PNAS 101:5598–5603. DOI: https://doi.org/10.1073/pnas.0400937101, PMID: 15034168

Luo W, Mayeux J, Gutierrez T, Russell L, Getahun A, Müller J, Tedder T, Parnes J, Rickert R, Nitschke L, Cambier J, Satterthwaite AB, Garrett-Sinha LA. 2014. A balance between B cell receptor and inhibitory receptor signaling controls plasma cell differentiation by maintaining optimal Ets1 levels. The Journal of Immunology 193:909–920. DOI: https://doi.org/10.7554/eLife.35074

Lutz C, Ledermann B, Kosco-Vilbois MH, Ochsenbein AF, Zinkernagel RM, Köhler G, Brombacher F. 1998. IgD can largely substitute for loss of IgM function in B cells. Nature 393:797–801. DOI: https://doi.org/10.1038/37176, PMID: 9655395

Maity PC, Blount A, Jumaa H, Ronneberger B, Rath M. 2015. B cell antigen receptors of the IgM and IgD classes are clustered in different protein islands that are altered during B cell activation. Science Signaling 8:ra93. DOI: https://doi.org/10.1126/scisignal.2005887, PMID: 26373673

Mansson JJ, Mauri C, Ehrenstein MR. 2005. Natural serum IgM maintains immunological homeostasis and prevents autoimmunity. Springer Seminars in Immunopathology 26:425–432. DOI: https://doi.org/10.1007/s00281-004-0187-x, PMID: 15611856

Mattila PK, Feest C, Depoil D, Treanor B, Montaner B, Ottopoby KL, Carter R, Justement LB, Bruckbauer A, Batista FD. 2013. The actin and tetraspanin networks organize receptor nanoclusters to regulate B cell receptor-mediated signaling. Immunity 38:461–474. DOI: https://doi.org/10.1016/j.immuni.2012.11.019, PMID: 23499492

Mayeux J, Skaug B, Luo W, Russell LM, John S, Saelee P, Abbasi H, Li QZ, Garrett-Sinha LA, Satterthwaite AB. 2015. Genetic Interaction between B, Lym, Lymc, and Plcb1 and effects on B cell responses to thymus-independent and -dependent antigens. Experimental Medicine 205:1081–1091. DOI: https://doi.org/10.1084/jem.20060087, PMID: 16606676

Mittelstadt PR, DeFranco AL. 1993. Induction of early response genes by cross-linking membrane Ig on B lymphocytes. Journal of Immunology 150:4822–4832. PMID: 8388422

Moore KW, Rogers J, Hunkapiller T, Early P, Nottenburg C, Weissman I, Bazin H, Wall R, Hood LE. 1981. Expression of IgD may use both DNA rearrangement and RNA splicing mechanisms. PNAS 78:1800–1804. DOI: https://doi.org/10.1073/pnas.78.3.1800, PMID: 6268286

Nguyen TT, Kläsener K, Zürn C, Castillo PA, Brust-Mascher I, Imai DM, Bevins CL, Reardon C, Reth M, Baumgarth N. 2017a. The IgM receptor FcμR limits tonic BCR signaling by regulating expression of the IgM BCR. Nature Immunology 18:321–333. DOI: https://doi.org/10.1038/nature.3677, PMID: 28135254

Nguyen TTT, Graf BA, Randall TD, Baumgarth N. 2017b. slgM-FcμR Interactions Regulate Early B Cell Activation and Plasma Cell Development after Influenza Virus Infection. The Journal of Immunology 199:1635–1646. DOI: https://doi.org/10.4049/jimmunol.1500026, PMID: 25769918

Nie Y, Waite J, Brewer F, Sunshine MJ, Littman DR, Zou YR. 2004. The role of CXCR4 in maintaining peripheral B cell compartments and humoral immunity. The Journal of Experimental Medicine 200:1145–1156. DOI: https://doi.org/10.1084/jem.20041185, PMID: 15520246

Nishizumi H, Taniuchi I, Yamanashi Y, Kitamura D, Ilic D, Mori S, Watanabe T, Yamamoto T. 1995. Impaired proliferation of peripheral B cells and induction of autoimmune disease in lyn-deficient mice. Immunity 3:549–560. DOI: https://doi.org/10.1016/1074-7613(95)90126-4, PMID: 7584145

Nitschke L, Kosco MH, Köhler G, Lamers MC. 1993. Immunoglobulin D-deficient mice can mount normal immune responses to thymus-independent and -dependent antigens. PNAS 90:1887–1891. DOI: https://doi.org/10.1073/pnas.90.5.1887, PMID: 8446604

Nutt SL, Hodgkin PD, Tarlinton DM, Corcoran LM. 2015. The generation of antibody-secreting plasma cells. Nature Reviews Immunology 15:160–171. DOI: https://doi.org/10.1038/nri.2015.25, PMID: 25698678

Paus D, Phan TG, Chan TD, Gardam S, Basten A, Brink R. 2006. Antigen recognition strength regulates the choice between extrafollicular plasma cell and germinal center B cell differentiation. The Journal of Experimental Medicine 203:1081–1091. DOI: https://doi.org/10.1084/jem.20060087, PMID: 16606676

Phan TG, Gardam S, Basten A, Brink R. 2005. Altered migration, recruitment, and somatic hypermutation in the early response of marginal zone B cells to T cell-dependent antigen. The Journal of Immunology 174:4567–4578. DOI: https://doi.org/10.4049/jimmunol.174.8.4567, PMID: 15184678

Pioli PD, Debnath I, Weis JJ, Weis JH. 2014. Zfp318 regulates IgD expression by abrogating transcription termination within the Ighm/Ighd locus. The Journal of Immunology 193:2546–2553. DOI: https://doi.org/10.4049/jimmunol.1401275, PMID: 25057009

Plunkett P, Deane JA, Difilippantonio MJ, Tarasenko T, Satterthwaite AB, Bolland S. 2006. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 312:1669–1672. DOI: https://doi.org/10.1126.science.1124978, PMID: 16709748
Quách TD, Manjarrez-Orduño N, Adlowitz DG, Silver L, Yang H, Wei C, Milner EC, Sanz I. 2011. Anergic responses characterize a large fraction of human autoreactive naive B cells expressing low levels of surface IgM. The Journal of Immunology 186:4640–4648. DOI: https://doi.org/10.4049/jimmunol.1001946, PMID: 21398610

Radaev S, Zou Z, Tolar P, Nguyen K, Nguyen A, Krueger PD, Stutzman N, Pierce S, Sun PD. 2010. Structural and functional studies of Igalphabeta and its assembly with the B cell antigen receptor. Structure 18:934–943. DOI: https://doi.org/10.1016/j.str.2010.04.019, PMID: 20696394

Reed JH, Jackson J, Christ D, Goodnow CC. 2016. Clonal redetermination of autoantibodies by somatic hypermutation away from self-reactivity during human immunization. The Journal of Experimental Medicine 213:1255–1265. DOI: https://doi.org/10.1084/jem.201519178, PMID: 27299445

Renshaw BR, Fanslow WC, Armitage RJ, Campbell KA, Liggitt D, Wright B, Davison BL, Maliszewski CR. 1994. Humoral immune responses in CD40 ligand-deficient mice. Journal of Experimental Medicine 180:1889–1900. DOI: https://doi.org/10.1084/jem.180.5.1889, PMID: 7964465

Roes J, Rajewsky K. 1993. Immunoglobulin D (IgD)-deficient mice reveal an auxiliary receptor function for IgD in antigen-mediated recruitment of B cells. Journal of Experimental Medicine 177:45–55. DOI: https://doi.org/10.1084/jem.177.1.45, PMID: 8418208

Sabouri Z, Perotti S, Spierings E, Humburg P, Yabas M, Bergmann H, Horikawa K, Roots C, Lambe S, Young C, Andrews TD, Field M, Enders A, Reed JH, Goodnow CC. 2016. IgD attenuates the IgM-induced anergy response in transitional and mature B cells. Nature Communications 7:13381. DOI: https://doi.org/10.1038/ncomms13381, PMID: 27830696

Sabouri Z, Schofield P, Horikawa K, Spierings E, Kipling D, Randall KL, Langley D, Roome B, Vazquez-Lombardi R, Rouet R, Hermes J, Chan TD, Brink R, Dunn-Walters DK, Christ D, Goodnow CC. 2014. Redemption of autoantibodies on anergic B cells by variable-region glycosylation and mutation away from self-reactivity. PNAS 111:E2567–E2575. DOI: https://doi.org/10.1073/pnas.1406974111, PMID: 24821781

Scapini P, Pereira S, Zhang H, Lowell CA. 2009. Multiple roles of Lyn kinase in myeloid cell signaling and function. Immunological Reviews 228:23–40. DOI: https://doi.org/10.1111/j.1600-065X.2008.00758.x, PMID: 19290919

Shaheen S, Wan Z, Li Z, Chau A, Li X, Zhang S, Liu Y, Yi J, Zeng Y, Wang J, Chen X, Xu L, Chen W, Wang F, Lu Y, Zheng W, Shi Y, Sun X, Li Z, Xiong C, et al. 2017. Substrate stiffness governs the initiation of B cell activation by the concerted signaling of PKCβ and focal adhesion kinase. eLife 6:e23060. DOI: https://doi.org/10.7554/eLife.23060, PMID: 28755662

Shlomchik MJ. 2008. Sites and stages of autoreactive B cell activation and regulation. Immunity 28:18–28. DOI: https://doi.org/10.1016/j.immuni.2007.12.004, PMID: 18199415

Skrzyczynska KM, Zhu JW, Weiss A. 2016. Positive regulation of Lyn kinase by CD148 is required for B cell receptor signaling in B1 but not B2 B cells. Immunity 45:1232–1244. DOI: https://doi.org/10.1016/j.immuni.2016.10.013, PMID: 27889108

Song H, Cerny J. 2003. Functional heterogeneity of marginal zone B cells revealed by their ability to generate both early antibody-forming cells and germinal centers with hypermutation and memory in response to a T-dependent antigen. The Journal of Experimental Medicine 198:1923–1935. DOI: https://doi.org/10.1084/jem.20031498, PMID: 14662910

Stadnwick J, Ee, Cancro MP. 2008. BAFF and the plasticity of peripheral B cell tolerance. Current Opinion in Immunology 20:158–161. DOI: https://doi.org/10.1016/j.immuni.2008.03.015, PMID: 18456486

Tabeta K, Hoebe K, Janssen EM, Du X, Georgel P, Crozat R, Mudd S, Mann N, Sovath S, Goode J, Shlomchik MJ, Herskovits AA, Portnoy DA, Cooke M, Tarantino LM, Wiltshire T, Steinberg BE, Grinstein S, Beutler B. 2006. Bruton’s tyrosine kinase uncouples B cell hyperresponsiveness from autoimmunity in lyn-/- mice. Nature Immunology 7:9–18. DOI: https://doi.org/10.1038/ni3175, PMID: 16415873

Tipton CM, Bucy SS, Darce J, Chida A, Ichikawa T, Gregoretti I, Schieferl S, Hom J, Jenks S, Feldman RJ, Mehr R, Wei C, Lee FE, Cheung WC, Rosenberg AF, Sanz I. 2015. Diversity, cellular origin and autoreactivity of autoantibodies on anergic B cells by variable-region glycosylation and mutation away from self-reactivity. Nature Immunology 16:534–543. DOI: https://doi.org/10.1038/ni.3141, PMID: 25848865

Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. 2003. Predominant autoantibody production by early human B cell precursors. Science 301:1374–1377. DOI: https://doi.org/10.1126/science.1086907, PMID: 12920303

Whyburn LR, Halcomb KE, Contreras CM, Lowell CA, Witte ON, Satterthwaite AB. 2003. Reduced dosage of Bruton’s tyrosine kinase uncouples B cell hyperresponsiveness from autoimmunity in lyn-/- mice. The Journal of Immunology 171:1850–1858. DOI: https://doi.org/10.4049/jimmunol.171.4.1850, PMID: 12902486

Winoto A, Littman DR. 2002. Nuclear hormone receptors in T lymphocytes. Cell 109 Suppl:S57–S66. DOI: https://doi.org/10.1016/S0092-8674(02)00710-9, PMID: 11983153

Xu Y, Harder KW, Huntington ND, Hibbs ML, Tarlinton DM. 2005. Lyn tyrosine kinase: accentuating the positive and the negative. Immunity 22:9–18. DOI: https://doi.org/10.1016/j.immuni.2004.12.004, PMID: 15664155

Zilberman J, Parameswaran R, Weiss A. 2012. Endogenous antigen tunes the responsiveness of naive B cells but not T cells. Nature 489:160–164. DOI: https://doi.org/10.1038/nature11311, PMID: 22902503